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A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure
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ABSTRACT
Whether perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS), two widely used and
biopersistent synthetic chemicals, are immunotoxic in humans is unclear. Accordingly, this article
systematically and critically reviews the epidemiologic evidence on the association between
exposure to PFOA and PFOS and various immune-related health conditions in humans. Twenty-four
epidemiologic studies have reported associations of PFOA and/or PFOS with immune-related
health conditions, including ten studies of immune biomarker levels or gene expression patterns,
ten studies of atopic or allergic disorders, five studies of infectious diseases, four studies of vaccine
responses, and five studies of chronic inflammatory or autoimmune conditions (with several studies
evaluating multiple endpoints). Asthma, the most commonly studied condition, was evaluated in
seven studies. With few, often methodologically limited studies of any particular health condition,
generally inconsistent results, and an inability to exclude confounding, bias, or chance as an
explanation for observed associations, the available epidemiologic evidence is insufficient to reach
a conclusion about a causal relationship between exposure to PFOA and PFOS and any immune-
related health condition in humans. When interpreting such studies, an immunodeficiency should
not be presumed to exist when there is no evidence of a clinical abnormality. Large, prospective
studies with repeated exposure assessment in independent populations are needed to confirm
some suggestive associations with certain endpoints.
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3 ), two of several perfluor-
oalkyl and polyfluoroalkyl substances (PFASs), were used
widely in industrial and commercial surfactant and
polymer applications beginning in the 1950s (Buck
et al. 2011). Because of the ubiquitous use and emission
of PFASs, these chemicals are commonly detected in the
environment, wildlife, and humans (Buck et al. 2011;
Butenhoff et al. 2006; Calafat et al. 2007a; Giesy and
Kannan 2001; Kannan et al. 2004). The pervasiveness of
PFOA and PFOS and their long clearance half-lives in
humans (Olsen et al. 2007) have provoked intense
interest in understanding the potential human health
impact of long-term exposure to these chemicals.
Guided largely by evidence of immunotoxic effects of
PFOA and PFOS in cellular and animal experimental
systems (Corsini et al. 2014; DeWitt et al. 2012), much
epidemiologic research in recent years has focused on
possible effects of these chemicals on various immune-
related health conditions in humans.
Industrial production and emission of PFOA and PFOS
in North America and Europe have ceased (U.S. EPA 2006),
and serum levels of both chemicals, especially PFOS, have
correspondingly declined over time in these regions
(Glynn et al. 2012; Kato et al. 2011; Nost et al. 2014; Olsen
et al. 2012; Yeung et al. 2013a, 2013b). However,
production of these chemicals or their precursors has
increased in parts of Asia (Li et al. 2015; Wang et al. 2014;
Xie et al. 2013; Zhang et al. 2012). In view of the ongoing
environmental release and persistence of PFOA and
PFOS, their widespread detection in humans, and
experimental evidence of animal immunotoxicity at
high administered doses, their potential effects on the
human immune system should be clarified. Therefore,
this systematic review was conducted to summarize and
evaluate the epidemiologic literature on PFOA and PFOS
in relation to human immunological conditions, and to
assess whether the evidence is sufficient to demonstrate
a causal relationship. As background for the review of
epidemiologic studies, this paper begins with a brief, non-
systematic review of animal studies of the immunotoxi-
city of PFOA and PFOS and the possible relevance of their
results to humans.
Overview of animal studies on the
immunotoxicity of PFOA and PFOS
Experimental studies of the immunotoxicity of PFOA and
PFOS have recently been reviewed, with some authors
concluding that these compounds can cause immune
suppression at doses that are potentially relevant to
highly exposed humans and wildlife (Corsini et al. 2014;
DeWitt et al. 2012). Earlier studies of high, acutely toxic
dietary doses of PFOA up to 75mg/kg/day resulted in
suppression of antigen-specific immunoglobulin M (IgM)
antibody production, splenic and thymic atrophy, and
altered T-cell phenotypic distribution in male C57BL/6
mice (Yang et al. 2002a, 2000, 2001); however, direct
immunotoxic effects could not be distinguished from
secondary effects of severe toxicity, effects on other
target organs, and stress. In male CD rats, by contrast, no
immunotoxic effects of PFOA were observed (Loveless
et al. 2008), even at acutely toxic oral doses up to 30mg/
kg/day that resulted in body weight loss, hepatomegaly,
and focal liver necrosis, indicating inter-species differ-
ences in the immune sensitivity to PFOA exposure.
Decreased IgM production in CD-1 mice administered 10
and 20mg/kg/day PFOA was probably secondary to
severe systemic toxicity and stress, as indicated by an
approximately 20% loss in body weight and a more than
3-fold increase in liver weight (Loveless et al. 2008).
At PFOA doses that were not acutely toxic, a 15-day
exposure study in C57BL/6J and C57BL/6N female mice
demonstrated dose-dependent PFOA-mediated suppres-
sion of IgM synthesis (which is involved mainly with
early, primary immunity), but not IgG synthesis (which is
involved mainly in secondary immunity) or delayed-type
hypersensitivity responses (Dewitt et al. 2008). The
lowest observed adverse effect level (LOAEL) was
3.75mg/kg/day PFOA from drinking water for 15 days,
a dose that led to approximately 74 000 ng/mL PFOA in
serum at 1 day post-exposure and 35 000 ng/mL serum
PFOA at 15 days post-exposure. The 1-day post-exposure
serum concentration is approximately 25–74 times
greater than that measured in occupationally highly
exposed humans (1000–3000 ng/mL) (Olsen et al. 2003;
Olsen et al. 2000; Olsen & Zobel 2007; Woskie et al.
2012), 200–2500 times greater than that measured in
environmentally exposed individuals living near a PFOA
production facility (30–350 ng/mL) (Emmett et al.
2006b; Frisbee et al. 2009), and 20 000 times greater
than that measured in the general U.S. population
(3–4 ng/mL) (Kato et al. 2011; Olsen et al. 2012).
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By contrast, no effect on antibody responses was
found in Sv/129 mice dosed with 30mg/kg/day PFOA in
drinking water for 15 days (DeWitt et al. 2009),
suggesting strain differences in susceptibility to PFOA.
Such inter-strain variability – or, alternatively, hetero-
geneity by route of exposure – may underlie the finding
that dermal exposure to 0.25–50mg/kg/day PFOA for
4 days increased total and ovalbumin-specific IgE levels
and ovalbumin-specific airway hyperreactivity in female
BALB/c mice (Fairley et al. 2007), whereas no effect of
oral PFOA exposure on delayed-type hypersensitivity
was seen in C57BL/6 mice (Dewitt et al. 2008).
Immunotoxicity studies of PFOS exposure have yielded
inconsistent results. As with PFOA, high PFOS doses
resulting in acute toxicity (body weight loss and
hepatomegaly) in C57BL/6 mice also caused splenic and
thymic atrophy and immunosuppression, including
depressed natural killer cell activity, lymphocyte prolif-
eration, and T-cell-dependent antibody response (Dong
et al. 2009; Zheng et al. 2009). However, such findings
cannot reliably be attributed to a direct immunotoxic
effect of PFOS.
One study demonstrated suppression of IgM produc-
tion via both T-cell-dependent and T-cell-independent
pathways in B6C3F1 male mice administered 0.05mg/kg/
day PFOS by oral gavage for 28 days (corresponding to a
serum concentration of 91.5 ng/mL PFOS) and female
mice administered 0.5mg/kg PFOS (corresponding to a
serum concentration of 666 ng/mL PFOS) (Peden-Adams
et al. 2008). The serum concentration in female mice is
comparable to that measured in occupationally exposed
humans (1000 ng/mL) (Olsen et al. 2003; Olsen & Zobel
2007), while that in male mice is within an order of
magnitude of serum concentrations observed in the
general U.S. population (9–30 ng/mL) (Frisbee et al.
2009; Kato et al. 2011; Olsen et al. 2012). Lymphocyte
proliferation, natural killer cell activity, and plasma
lysozyme activity were not suppressed by PFOS in this
study; the latter two parameters were increased in male
and female mice, respectively. Another study in female
B6C3F1 mice reported impaired immunity to influenza A
virus (H1N1) following a 21-day oral gavage exposure to
either 0.005 or 0.025mg/kg/day PFOS (resulting in 189 or
670 ng/mL plasma PFOS, respectively) (Guruge et al.
2009).
By contrast, dietary exposure of male B6C3F1 male
mice to 7mg/kg/day PFOS for 28 days, resulting in a
serum concentration of 11 600 ng/mL PFOS (more than
10 times the average in occupationally exposed
humans), had no effect on IgG or IgM synthesis (Qazi
et al. 2010). This study also found no effect of PFOS on
the total number of circulating leukocytes or the number
and phenotypic distribution of thymic or splenic cells.
Likewise, dietary exposure of male and female Sprague-
Dawley rats to 0.14–7.58mg/kg/day PFOS for 28 days,
resulting in serum PFOS levels of 470–29 900 ng/g in
males and 950–43 200 ng/g in females, did not result in a
dose-related suppression of serum total IgG, IgM, IgA,
or IgE levels, specific IgG synthesis, or delayed-
type hypersensitivity responses (Lefebvre et al. 2008).
Differences in species, strains, and vehicles of adminis-
tration may play a role in the inconsistency of results.
In a study of B6C3F1 pups born from the pairing of
female C57BL/6N mice with male C4H/HeJ mice, where
dams were gavaged with 0.1, 1, or 5mg/kg/day PFOS on
gestational days 1–17, natural killer cell activity was
suppressed in 8-week-old male offspring at the 1 and
5mg/kg/day doses and in female offspring at the 5mg/
kg/day dose (Keil et al. 2008). In addition, specific IgM
production was suppressed at 5mg/kg/day (a dose
sufficient to cause hepatomegaly at 4 weeks) in males,
but not females. Serum PFOS concentrations were not
reported in this study.
The immunotoxic mode of action of PFOA and PFOS in
animals remains to be elucidated. Ligand activation of
the peroxisome proliferator-activated receptor alpha
(PPARa), and possibly also the constitutive androstane
receptor (CAR) and the pregnane X receptor (PXR), is a key
event in some PFOA- and PFOS-mediated toxicities in
laboratory animals (Corton et al. 2014; Elcombe
et al. 2010, 2012, 2014; Klaunig et al. 2003; Klaunig et al.
2012). Given inter-species differences in receptor speci-
ficity, receptor activity, and ligand binding and activation,
the relevance of these signal transduction pathways to
humans is unclear. For example, most of the mechanistic
steps shown to be involved in rodent hepatocarcinogen-
esis by PPARa and CAR activators probably
do not occur in humans (Corton et al. 2014; Elcombe
et al. 2014; Klaunig et al. 2003; Klaunig et al. 2012).
However, the role of PPARa, CAR, and PXR in mediating
PFOA- and PFOS-induced immunotoxicity is not estab-
lished (DeWitt et al. 2009). Some studies suggest that
immunotoxic effects of PFOA may depend on PPARa in
some mouse strains but not others (Corsini et al. 2014;
Yang et al. 2002b).
Extrapolation of findings from laboratory animals to
humans is also hindered by substantial species and sex
differences in the pharmacokinetics of PFOA and PFOS
(Butenhoff et al. 2006; Kennedy et al. 2004), including
clearance half-lives that vary by several orders of
magnitude (Chang et al. 2012; Olsen et al. 2007). This
variation appears to be at least partly due to differences
in renal tubular reabsorption processes (Han et al. 2012).
Such discrepancies highlight the importance of using
serum PFOA and PFOS concentrations to represent
exposure in both animals and humans.
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In summary, under experimental conditions, PFOA
and PFOS can cause immune suppression in laboratory
animals, although results vary by species, strain, sex, and
route of exposure, as well as the type of outcome
measured. Experimental LOAELs were above concentra-
tions measured in occupationally exposed humans for
PFOA, but near or below those measured in occupa-
tionally exposed humans for PFOS. In the absence of an
established mode of action/adverse outcome pathway,
the relevance of these findings to human health
outcomes is not yet known. Therefore, epidemiologic
studies of PFOA and PFOS should also be assessed for
evidence of immunotoxic effects in humans.
Literature search and data extraction methods
The overarching causal question of interest for this
review is whether PFOA and PFOS are causally related to
adverse immunological health conditions in humans.
The literature search strategy, which was designed
according to recommended best practices (Rhomberg
et al. 2013), is described in detail in the Supplemental
Materials. Articles eligible for inclusion were original
epidemiologic research studies that reported associa-
tions between exposure specifically to PFOA and/or
PFOS and any health outcome primarily affecting the
immune system. Based on a search of Scopus and
MEDLINE, 24 relevant studies published as of September
1 2015 were identified for inclusion (Anderson-Mahoney
et al. 2008; Ashley-Martin et al. 2015; Costa et al. 2009;
Dong et al. 2013; Emmett et al. 2006b; Fei et al. 2010;
Grandjean et al. 2012; Granum et al. 2013; Humblet et al.
2014; Innes et al. 2011; Kielsen et al. 2015; Leonard et al.
2008; Lin et al. 2011; Looker et al. 2014; Okada et al.
2012, 2014; Olsen et al. 2003; Osuna et al. 2014; Pennings
et al. 2015; Smit et al. 2015; Steenland et al. 2013, 2015;
Uhl et al. 2013; Wang et al. 2011).
Details about the methods of each relevant study,
including location, dates, design, subjects, comparison
populations, exposure and outcome assessment, fund-
ing source, and other aspects, were abstracted by
E.T.C. and independently checked by L.E. (see
Acknowledgments), and are provided in Supplemental
Table 1. When appropriate, additional information was
collected from online supplements and earlier, more
detailed publications. Some unpublished information
was obtained through personal communication with the
lead author of one study (Granum et al. 2013). Results
from each relevant study, including estimates of
association and potential confounders included in
multivariate models, are provided in Tables 1–5, which
summarize results separately for studies of immune
biomarkers or gene expression patterns (Table 1), atopic
conditions (Table 2), infections (Table 3), vaccine
response (Table 4), and autoimmune and inflammatory
conditions (Table 5). Results from multivariate adjusted
statistical models, if presented, are shown in the tables in
lieu of results from unadjusted or minimally adjusted
models.
Methodological issues in epidemiologic studies
of PFOA, PFOS, and immune conditions
Following data extraction, the quality of individual
epidemiologic studies was evaluated based on the
validity and reliability of outcome assessment and
exposure assessment, control of confounding, potential
for selection bias, and appropriateness of the statistical
approach. The following sections provide a detailed
discussion of issues related to each of these methodo-
logical features as they pertain to epidemiologic studies
of PFOA and/or PFOS exposure and immunological
health conditions.
Outcome assessment
Numerous and disparate immune-related endpoints
were investigated in the epidemiologic studies of
PFOA or PFOS and immune conditions included in
this review. Methods used to assess these endpoints are
fundamental to the validity of study results, as well as to
the interpretation of the clinical and public health
relevance of findings.
Clinical perspective on assessment of immune
impairment
The specific evaluation tools that allow clinical immuno-
logists to examine the health of a patient’s immune
system vary depending upon the clinical question that is
being asked. The first and most important question
concerns the overall health of the patient who is being
evaluated, with particular emphasis on the function of
the immune system; this process is the same for the
evaluation of any other organ in the body. The function
of the immune system is, grossly, to defend the body
from foreign or unwanted substances and to prevent
infection. Thus, a clinical immunologist aims to evaluate
whether the patient’s frequency or types of infection
deviate from those of otherwise comparable individuals.
This concept is so important that the 10 cardinal
warning signs of an abnormality in the immune system
(i.e. primary immunodeficiency) are centered on fre-
quencies and types of infections (Supplemental Table 2)
(Jeffrey Modell Foundation 2013). For the patient who
displays any two of these 10 warning signs, the
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evaluation of the immune system is relatively straight-
forward. Given the specialization of the immune system,
the signs can give clues regarding the type of
immunodeficiency. For example, common infections of
the upper and lower respiratory tract, excessive diarrhea,
and to some extent oral infections may point to
problems with fighting bacteria, i.e. antibody-mediated
immunity. Uncommon opportunistic infections may
point to problems with fighting fungal and fungal-like
infections, i.e. cell-mediated immunity. Both types of
infections may be seen if antibody-mediated and cell-
mediated immunity are simultaneously affected, as in
severe combined immunodeficiency or severe HIV/AIDS.
Thus, the most important part of any evaluation of the
immune system is a thorough patient history. This
history allows the selection of a series of laboratory
evaluations, including a blood draw in most cases, to
confirm the diagnosis of immunodeficiency, identify the
abnormal part(s) of the immune system, and point to an
appropriate therapeutic intervention. Even when the
immune abnormality is secondary, as with a malignancy
of the immune system or poisoning of the immune
system, the signs, symptoms, and evaluation remain the
same; that is, a deficit in immunoreactivity leads to
infection, which is then evaluated as noted above.
Immunodeficiency cannot be presumed to exist in the
absence of evidence of such a clinically recognizable
abnormality.
The question arises, then, of whether is it appropriate
to evaluate the immune system when there is no
observable abnormality simply because of an exposure
(real or suspected) that has the potential to be
immunotoxic. In this situation, a clinical immunologist
might do the same series of tests as outlined above, but
the question is completely different: instead of asking
what part of the immune system is not working properly,
based on clinical evidence of an abnormality, the concern
is whether there is some part of the immune system that
is abnormal, and if so, whether that abnormality will result
in disease. From a clinician’s perspective, if an abnorm-
ality is noted but it does not predict disease, then at best
time and money are wasted, and at worst a patient is
informed erroneously that he or she is sick or will get sick
when this is not true, thereby breaking the rule of
‘‘primum non nocere’’ – above all do no harm.
Outcome assessment of immune biomarkers
Whereas clinical evaluation of immunodeficiency focuses
on the frequencies and types of infection, the epide-
miologic studies of PFOA and PFOS included in this
review investigated a variety of immune-related clinical















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CRITICAL REVIEWS IN TOXICOLOGY 293
well as non-clinical outcomes. Non-clinical endpoints
that were studied include biological markers of immune
function, such as levels of leukocytes, immunoglobulins
(Ig), and immune-related proteins, measured using
standard laboratory hematological tests (Ashley-Martin
et al. 2015; Costa et al. 2009; Dong et al. 2013; Emmett
et al. 2006b; Granum et al. 2013; Lin et al. 2011; Okada
et al. 2012; Olsen et al. 2003; Wang et al. 2011). These are
well-established, objectively measured markers of
immune function that are unlikely to be subject to
systematic bias. Similarly, studies of the immune
response to vaccination used standard laboratory
assays to measure specific antibody levels (Grandjean
et al. 2012; Granum et al. 2013; Kielsen et al. 2015; Looker
et al. 2014). Another study measured autoantibody titers
as less well-established potential biomarkers of tissue
damage (Osuna et al. 2014), and one evaluated gene
expression patterns that might be indicative of immu-
nomodulation (Pennings et al. 2015).
However, many standard immune biomarkers, such as
leukocyte counts (Saunders 1985; Statland et al. 1978;
Winkel et al. 1981) and C-reactive protein (DeGoma et al.
2012; Platz et al. 2010), are known to fluctuate
substantially within individuals over time and under
different conditions. [Variation in leukocyte counts has
also been documented among laboratories, but appears
to be less than physiological variability (Mandigo et al.
1995).] Vaccine-induced antibody levels can also vary
extensively over time (Rose et al. 2013; Schauer et al.
2003; Skowronski et al. 2008), as can autoantibody levels
(Meroni et al. 2014) and gene expression patterns (which
vary even among genetically identical cells) (Maheshri &
O’Shea 2007; Munsky et al. 2012). Therefore, just as a
single exposure measurement may not be sufficiently
informative, a one-time measurement of any given
immune biomarker level, antibody titer, or gene expres-
sion pattern may provide an erroneous depiction of a
person’s immune function. Repeated testing is needed
to capture immune function more fully. Moreover, some
components of the immune system are not readily
assayable, either because the appropriate technology
has not yet been developed or because some immune
cells, such as antigen-presenting cells, do not circulate in
the peripheral blood and therefore cannot be sampled
by a simple blood draw.
Another issue related to immune biomarkers and
antibody levels is whether small but statistically sig-
nificant changes in these endpoints, when analyzed on a
continuous scale, are clinically meaningful, particularly
when most or all subjects are within the normal range.
Some studies attempted to address this issue by also
analyzing outcomes dichotomized relative to standard































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CRITICAL REVIEWS IN TOXICOLOGY 303
outside the reference range indicate immune abnorm-
alities (Emmett et al. 2006b; Grandjean et al. 2012;
Looker et al. 2014). A limitation of this approach is that a
reference range is typically determined based on the
mean plus or minus two standard deviations calculated
from a group of healthy adults or children. By definition,
5% of the normal population falls outside of such a
reference range (AACC 2015). The only way to determine
whether a given value outside a reference range is truly
‘‘abnormal’’ is to associate it with a clinical abnormality,
yet this has not been done in most epidemiologic
studies of immune biomarkers. Studies also have not
demonstrated whether immune parameters measured in
clinically normal individuals can accurately predict the
risk of future immunological diseases. Given the immune
system’s capacity for repair and regeneration, apparent
immune abnormalities that are detected at one point in
time may even resolve before producing any adverse
clinical health effect. Thus, biomarkers that do not
accurately diagnose or predict the presence or absence
of a clinical health condition are not clinically useful.
Outcome assessment of clinical immune conditions
Studies of PFOA and PFOS in relation to clinically
recognizable immune conditions discussed in this
review, including atopic, infectious, autoimmune, and
inflammatory disorders, mostly used self- or parent-
reported information as a basis for outcome assessment
(Anderson-Mahoney et al. 2008; Granum et al. 2013;
Humblet et al. 2014; Innes et al. 2011; Looker et al. 2014;
Okada et al. 2012, 2014; Smit et al. 2015; Steenland et al.
2013, 2015; Uhl et al. 2013; Wang et al. 2011). The
majority did not validate self-reported data based on
medical records or other official sources, such that
outcome misclassification was probable but unquantifi-
able. Study validity would be particularly threatened in
studies where participants were probably aware of
whether they were relatively highly exposed to PFOA
from a contaminated public water supply and/or from
their workplace (Anderson-Mahoney et al. 2008; Emmett
et al. 2006b; Innes et al. 2011; Looker et al. 2014;
Steenland et al. 2013, 2015). In these studies, self-
reported outcomes might be influenced by the percep-
tion that higher exposure could increase risk of adverse
health conditions, thereby biasing associations in a
positive direction.
Even in the studies that attempted to validate self-
reported outcomes (Steenland et al. 2013, 2015), only
positive self-reports were compared with medical
records in a subset of subjects, excluding those who
did not consent to medical records retrieval or whose












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CRITICAL REVIEWS IN TOXICOLOGY 309
negative self-reports. A substantial proportion of sub-
jects with self-reported conditions were excluded due to
the absence of confirmation. Thus, bias due to differ-
ential outcome misclassification remained possible in
these studies if factors related to validation differed by
exposure level – although information was not provided
to assess this possibility. Additionally, even if physician’s
diagnoses of certain immune conditions were accurately
self-reported by study participants, the probability of
observing such endpoints could be influenced by
physicians’ diagnostic criteria or acuity, or by individuals’
access to health care. Therefore, associations of PFOA or
PFOS exposure with health care quality or usage (e.g.
mediated through socioeconomic status (Nelson et al.
2012; Tyrrell et al. 2013) or occupation) could concei-
vably be responsible for observed associations with
certain physician-diagnosed immune conditions.
A few studies of clinical immunological disorders
ascertained outcomes based on death certificates
(Leonard et al. 2008), hospital discharge diagnoses (Fei
et al. 2010), or a confirmed physician’s diagnosis (Dong
et al. 2013). Such objectively collected outcome data are
generally less prone to bias than self-reported informa-
tion, although differential misclassification can be
induced if physicians are aware of subjects’ exposure
status. Hospital discharge and mortality data are not
sensitive for capturing certain immune conditions, such
as asthma and common infections, which usually do not
result in hospitalization or death. Therefore, results that
rely on these data may not be generalizable to less
severe conditions. Moreover, some associations may be
observed due to an influence of the exposure (or related
conditions) on the severity of disease (which would still
be important to identify) or the probability of seeking
medical attention or being hospitalized, rather than an
effect on disease development itself.
Exposure assessment
Exposure assessment is as vital to the validity and
interpretation of a study as is outcome assessment. Of
the 24 epidemiologic studies included in this review, 19
measured PFOA and/or PFOS in the serum or plasma of
individual subjects using liquid chromatography tandem
mass spectrometry, the standard method for quantita-
tive analysis of these chemicals (Ashley-Martin et al.
2015; Dong et al. 2013; Emmett et al. 2006b; Fei et al.
2010; Grandjean et al. 2012; Granum et al. 2013; Humblet
et al. 2014; Innes et al. 2011; Kielsen et al. 2015; Lin et al.
2011; Looker et al. 2014; Okada et al. 2012, 2014; Olsen
et al. 2003; Osuna et al. 2014; Pennings et al. 2015; Smit
et al. 2015; Uhl et al. 2013; Wang et al. 2011). The other
five studies estimated PFOA exposure based on place of
residence (Anderson-Mahoney et al. 2008), employment
at a polymer manufacturing plant (Leonard et al. 2008)
or within a PFOA production department at another
chemical production plant (Costa et al. 2009), or an
environmental fate and transport model for PFOA linked
with a pharmacokinetic model and individual-level
residential history and water consumption data, vali-
dated against recent serum PFOA measurements in a
subset of the study subjects (Steenland et al. 2013,
2015). Compared with the five studies that used
exposure estimates or proxies, the studies that measured
PFOA and/or PFOS levels had the advantage of direct
exposure assessment, thereby theoretically reducing
exposure misclassification.
Among the 19 studies with serum or plasma PFOA
and/or PFOS measurements, eight were cross-sectional
(Emmett et al. 2006b; Humblet et al. 2014; Innes et al.
2011; Kielsen et al. 2015; Lin et al. 2011; Looker et al.
2014; Olsen et al. 2003; Uhl et al. 2013), one was
retrospective (Dong et al. 2013), and the remainder were
prospective in design (Ashley-Martin et al. 2015; Fei et al.
2010; Grandjean et al. 2012; Granum et al. 2013; Okada
et al. 2012, 2014; Osuna et al. 2014; Pennings et al. 2015;
Smit et al. 2015; Wang et al. 2011). Prospective cohort
studies benefit from measuring exposures prior to the
diagnosis of health conditions, thereby ensuring that the
temporal sequence of exposure and outcome is logically
consistent with a potential causal effect. By contrast,
when the exposure of interest is measured concurrently
with the outcome (as in cross-sectional studies) or after
the outcome has been ascertained (as in retrospective
case-control studies), it may be difficult to determine
which preceded the other in time, thereby prohibiting
conclusions about causation. In the case of circulating
PFOA and PFOS levels, reverse causation is a possible
concern, given that disease processes or corresponding
treatments could conceivably affect physiological clear-
ance of these chemicals, and possibly also changes in
behavioral patterns related to exposure (e.g. tap water
consumption). However, such mechanisms are not well
studied, and the potential direction and magnitude of
bias are unknown.
Another issue related to exposure assessment is
whether a single measurement of circulating PFOA or
PFOS is etiologically relevant, even if measured prior to
onset of the health condition of interest. Among all
epidemiologic studies included in this review, only two
(Grandjean et al. 2012; Osuna et al. 2014) analyzed PFOA
and PFOS concentrations at more than one time point.
One study found pairwise Pearson correlations of 0.19
for PFOA and 0.27 for PFOS measured in serum from
310 E. T. CHANG ET AL.
mothers during pregnancy and in children at age 5 years
(Grandjean et al. 2012), while the other found correla-
tions of 0.33 for PFOA and 0.28 for PFOS measured in
maternal prenatal serum and in child serum at age
7 years (Osuna et al. 2014). These results suggest limited
correlation between maternal and childhood exposure,
perhaps due to changes in exposure levels over the
course of early childhood, the effects of rapid growth
and a high renal clearance rate in early childhood, or
individual variability in uptake (during pregnancy) and
clearance (during and after pregnancy). PFOA and PFOS
have clearance half-lives of approximately 2.5 years and
4.8 years, respectively, in humans (Bartell 2012; Chang
et al. 2012; Olsen et al. 2007), indicating that there is
little fluctuation within individuals in the presence of
constant exposure sources. However, whether those
sources are indeed constant is unknown and perhaps
unlikely, given the widespread use and release of these
chemicals (Buck et al. 2011). In the absence of adequate
evidence, unanswered questions are the degree to
which circulating PFOA and PFOS levels change within
individuals over time, and whether specific time
windows exist during which exposure to PFOA or PFOS
might have an effect on the development of immune
disorders in humans. To the extent that a single
exposure measurement does not capture individual
variation in circulating PFOA and PFOS levels and is
not taken during an etiologically important time
window, the pertinent exposure will be misclassified.
Confounding
Control for confounding varied substantially among
epidemiologic studies in this review, ranging from no or
minimal adjustment (Anderson-Mahoney et al. 2008;
Ashley-Martin et al. 2015; Emmett et al. 2006b; Granum
et al. 2013; Kielsen et al. 2015; Leonard et al. 2008;
Looker et al. 2014; Osuna et al. 2014; Pennings et al.
2015) to adjustment for at least 10 covariates potentially
related to the exposure and outcome (Fei et al. 2010;
Innes et al. 2011; Lin et al. 2011; Okada et al. 2012). In
virtually any observational study, but especially those
that adjust for no or few potential confounders,
confounding cannot be eliminated; that is, an exposure
and an outcome can appear to be associated due to
independent associations with a third, unmeasured or
incompletely adjusted variable. Indeed, several authors
acknowledged that uncontrolled confounding, including
residual confounding due to imprecise adjustment,
remained a potential explanation for observed results
(e.g. (Anderson-Mahoney et al. 2008; Ashley-Martin et al.
2015; Dong et al. 2013; Humblet et al. 2014; Innes et al.
2011; Leonard et al. 2008; Steenland et al. 2013; Uhl et al.
2013; Wang et al. 2011)).
Although some sociodemographic and behavioral
determinants of PFAS levels have been identified
(Calafat et al. 2007b; Emmett et al. 2006a; Eriksen et al.
2011; Jain 2013, 2014; Nelson et al. 2012; Tyrrell et al.
2013), the list is almost certainly incomplete, and
influential factors – as well as the direction and
magnitude of their associations – may vary across
populations. In addition, risk factors for immune condi-
tions are incompletely recognized. Thus, the potential
effect of confounding on observed estimates is
complex and difficult to quantify. Nevertheless, espe-
cially in studies with minimal adjustment for covariates,
the potential influence of confounding should
be taken into account when interpreting positive,
negative, and null reported results. Sensitivity analysis
comparing results with different covariate adjustment
strategies could help to clarify the impact of specific
confounders.
Selection bias
Other than bias due to confounding or systematic
differences in the reporting of outcomes, discussed
above, selection bias is another potential concern in
some of the studies discussed in this review. Particularly
in cross-sectional and case-control studies, in which
subjectsmay be aware of their health status and exposure
status at the time of enrollment, selection bias may arise if
the decision to participate is influenced by this aware-
ness. Even if the exposure and outcome themselves do
not directly affect participation rates, selection bias can
occur if participation is influenced by other factors, such
as sociodemographic characteristics, that are associated
with the exposure and outcome. In some cross-sectional
and case-control studies, fewer than half of eligible
subjects elected to participate (Anderson-Mahoney et al.
2008; Emmett et al. 2006b; Lin et al. 2011), and none had
participation rates over 75% after accounting for exclu-
sions due to missing data (Innes et al. 2011; Olsen et al.
2003) (omitting those that did not report participation
rates (Costa et al. 2009; Dong et al. 2013; Humblet et al.
2014; Kielsen et al. 2015; Uhl et al. 2013)). In the presence
of substantial non-participation, the potential magnitude
of selection bias is greater.
In prospective cohort studies, the likelihood of
selection bias due to unequal participation rates is
lower because subjects are recruited prior to the onset
of health conditions. Selection bias may occur at the
time of enrollment if the decision to participate is
affected by one’s awareness of their future disease risk
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(e.g. due to having a positive family history) and
exposure level, or factors associated with both, but this
is a less likely scenario. Additionally, selection bias can
occur during follow-up if the decision to drop out of the
study is related to exposure and outcome. Therefore,
reported study follow-up rates of 12–89% among
subjects originally enrolled in prospective cohorts
(Ashley-Martin et al. 2015; Grandjean et al. 2012;
Granum et al. 2013; Okada et al. 2012, 2014; Pennings
et al. 2015; Smit et al. 2015; Steenland et al. 2013, 2015;
Wang et al. 2011) raise varying degrees of concern about
potential selection bias.
Selection bias can also arise if the source populations
for exposed and unexposed subjects differ system-
atically by outcome status, or if the source populations
for cases and controls differ systematically by exposure
status, independently of any true association between
the exposure and outcome. Although most studies used
internal comparison groups, thereby avoiding bias due
to non-comparable source populations, studies suscep-
tible to this bias were a case-control study of children
with asthma diagnosed at one of two hospitals,
compared with children without asthma selected from
seven public schools in the same geographic region of
Taiwan (Dong et al. 2013); and especially a cross-
sectional study of volunteers included in a class action
lawsuit due to their residence near a PFOA-contami-
nated river in Ohio and West Virginia, compared with
nationally representative survey data (Anderson-
Mahoney et al. 2008).
Statistical considerations
Any given statistical association may be due to chance. In
studies that test a large number of hypotheses, the
expected number of false-positive results (typically set at
5%) increases correspondingly. Selective reporting of
statistically significant results and omission of non-
significant results, a common practice in epidemiologic
studies (Kavvoura et al. 2007), can lead to undercounting
of the total number of tests conducted and the
corresponding expected number of false-positive find-
ings. Especially when a posteriori analyses are conducted
with exposures and outcomes classified in several ways or
focusing on various subgroups of subjects in an effort to
detect significant results, chance should be mentioned as
a plausible explanation for any statistically significant
result. Replication of findings in multiple independent
study settings is critical to determining whether an
association is unlikely to be explained by chance.
Conversely, low statistical power should be taken into
account as an explanation for statistically non-significant
findings in studies with a small number of subjects.
However, because sampling and measurement error
cannot be assumed to be completely at random, one
cannot assume that a larger study would necessarily yield
the same relative risk point estimates with greater
statistical precision. Moreover, the lower the power of a
study, the lower the probability that an observed,
nominally statistically significant association is due to a
true effect; that is, significant associations in smaller
studies, on average, are more likely to be false (Button
et al. 2013).
In summary, key characteristics for evaluating the
quality of an epidemiologic study are outcome assess-
ment methods, exposure assessment methods, control
for confounding, potential for selection bias, and appro-
priateness of the statistical approach and its presentation.
In the studies of associations between PFOA and/or PFOS
and immune conditions, issues such as the clinical
relevance, intra-individual variability, temporal sequence,
and validity of outcome and exposure measures; the
potential direction and magnitude of bias due to
uncontrolled confounding and selection bias; and the
roles of selective reporting, insufficient power, and
chance should be taken into account when interpreting
the results of each study. Those results are summarized in




Nine studies reported associations between serum or
plasma levels of PFOA and/or PFOS and various
circulating immune biomarkers measured using stan-
dard assays (Table 1) (Ashley-Martin et al. 2015; Costa
et al. 2009; Dong et al. 2013; Emmett et al. 2006b;
Granum et al. 2013; Lin et al. 2011; Okada et al. 2012;
Olsen et al. 2003; Wang et al. 2011). One other study
reported associations of PFAS (including PFOA and
PFOS) levels with gene expression patterns, which
were in turn related to immune-related outcomes
(Pennings et al. 2015); this study is discussed in this
section because, like biomarkers, gene expression
patterns are nonspecific indicators that do not necessa-
rily correspond to a clinically recognizable condition.
Only four specific biomarkers were evaluated in more
than one study: white blood cell count, total IgE,
eosinophil count, and C-reactive protein. Five studies
(Ashley-Martin et al. 2015; Granum et al. 2013; Okada
et al. 2012; Pennings et al. 2015; Wang et al. 2011)
involved prospective follow-up of birth cohorts in which
prenatal or perinatal PFOA and PFOS levels were
analyzed in relation to outcomes measured subse-
quently at birth or in early childhood (although Okada
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et al. (2012) collected an unspecified number of
maternal serum samples after delivery). The remaining
five studies were cross-sectional or case-control in
design and analyzed PFOA, PFOS, and biomarker levels
measured at the same time, even if repeated specimens
were collected (Costa et al. 2009; Dong et al. 2013;
Emmett et al. 2006b; Lin et al. 2011; Olsen et al. 2003).
Thus, the latter studies were unable to establish the
temporal sequence between PFOA or PFOS concentra-
tions and immune biomarkers.
White blood cell count
No significant association between serum PFOA or PFOS
and white blood cell count was detected in a cross-
sectional analysis of medical surveillance examination
data from 518 workers at two fluorochemical manufac-
turing facilities in Belgium and the United States
(quantitative results not reported) (Olsen et al. 2003).
Likewise, no significant difference in white blood cell
count was detected in a cross-sectional analysis of
medical surveillance examination data comparing
34 workers currently employed in a PFOA production
department at a chemical plant in Italy and up to
107 workers never occupationally exposed to PFOA
(regression coefficient for exposed versus unexposed
¼ 0.58 109/L, 95% confidence interval [CI]¼ –0.19,
1.35), nor was a significant association detected between
concurrently measured serum PFOA level and white
blood cell count (coefficient¼ 0.029 109/L per
1000 ng/mL PFOA, 95% CI¼ –0.011, 0.071) (Costa et al.
2009). In a cross-sectional study of 371 residents in a
Mid-Ohio Valley water district contaminated with
PFOA from a nearby polymer manufacturing plant,
serum PFOA was not significantly associated with
higher white blood cell count assessed as a continuous
outcome (coefficient¼ 0.0004 [units not reported],
¼ 0.09, p¼ 0.08), and no significant difference in
serum PFOA was observed between those with abnor-
mal and normal white blood cell counts (p¼ 0.64)
(Emmett et al. 2006b).
All three of these studies were limited by their cross-
sectional design and use of one-time exposure and
outcome measurements. Participation rates of 75% and
52% in the study by Olsen et al. (2003) and 36–49% in
the study by Emmett et al. (2006b) (participation rates
were not reported by Costa et al. (2009)) could have
produced selection bias, and Emmett et al. (2006b) did
not control for any potential confounders. Finally, by not
assessing individual- or group-level exposures, the study
by Costa et al. (2009) implicitly assumed that all PFOA
production workers were similarly exposed.
Nevertheless, the generally consistent null results
suggest no substantial, detectable effect of PFOA or
PFOS on total white blood cell count.
Childhood IgE
The relationship between PFOA or PFOS levels and
newborn or childhood total IgE levels was reported in
four studies (Table 1) (Ashley-Martin et al. 2015; Dong
et al. 2013; Okada et al. 2012; Wang et al. 2011). In a
prospective birth cohort of 244 children in Taiwan, log-
transformed cord serum PFOA and PFOS levels mea-
sured at delivery were not significantly associated with
serum total IgE levels at age 2 years (regression
coefficient¼ 0.037 kU/L per 1 log ng/mL PFOA,
p¼ 0.870; coefficient¼ 0.251 kU/L per 1 log ng/mL
PFOS, p¼ 0.147) (Wang et al. 2011). However, in a
cross-sectional analysis of this cohort, significant positive
associations of log-transformed cord serum PFOA and
PFOS with cord serum total IgE at birth were detected
among boys (PFOA coefficient¼ 0.206, 95% CI¼ 0.047,
0.702; PFOS coefficient¼ 0.175, 95% CI¼ 0.004, 0.704),
but not girls (PFOA coefficient¼ 0.067, p¼ 0.823; PFOS
coefficient¼ 0.151, p¼ 0.616).
Discordant heterogeneity by sex was reported in a
prospective birth cohort study of 343 Japanese mother–
child pairs, among whom log10-transformed third-
trimester maternal prenatal serum PFOA was inversely
associated with cord serum total IgE at birth in quadratic
and cubic (but not linear) models for girls, suggesting
a curvilinear relationship (linear coefficient¼ 0.766 IU/mL
per 1 log10 ng/mL PFOA, 95% CI¼ 0.104, 1.428; quadratic
coefficient¼ –1.429, 95% CI¼ –2.416, –0.422; cubic
coefficient¼ –3.078, 95% CI¼ –5.431, –0.726), whereas
no significant association was observed in boys (Okada
et al. 2012). In both boys and girls in this study, no
significant association was found between maternal
prenatal serum PFOS levels and cord serum IgE levels.
In a cross-sectional analysis within a case-control
study of 231 children with physician-diagnosed asthma
and 225 controls in Taiwan, higher quartiles of child
serum PFOA and PFOS were not significantly associated
with serum total IgE among controls (Ptrend¼ 0.123 and
0.404, respectively), but statistically significant positive
exposure-response trends with both PFOA and PFOS
were seen in asthmatic children (Ptrend¼ 0.005 and 0.008,
respectively) (Dong et al. 2013).
A third prospective birth cohort study, in which
maternal first-trimester plasma PFOA and PFOS levels
were studied in relation to cord plasma IgE levels in 1242
mother–infant pairs in Canada, found no significant
associations (odds ratio (OR) for elevated IgE 0.5 kU/L
per unit increase in log10-transformed maternal
PFOA¼ 1.1, 95% credible interval (CrI)¼ 0.6, 1.9; OR for
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maternal PFOS¼ 1.1, 95% CrI¼ 0.6, 1.9) (Ashley-Martin
et al. 2015). Unlike the results of Okada et al. (2012),
these null associations did not vary appreciably in
analyses stratified by infant sex.
Three of these studies are strengthened by their
prospective design (Ashley-Martin et al. 2015; Okada
et al. 2012; Wang et al. 2011), but remain constrained by
the reliance on a single measurement of exposure and
outcome per subject. The case-control study (Dong et al.
2013), besides being limited by its reliance on serum
PFOA, PFOS, and total IgE levels measured simulta-
neously, was susceptible to selection bias due to the
differently defined case and control source populations,
as well as nonparticipation. Given the contradictory
evidence of subgroup heterogeneity and inconsistency
in the direction and magnitude of the reported
associations, if any, it remains uncertain whether PFOA
or PFOS affects total IgE levels in all children or in certain
susceptible subgroups.
Eosinophil count
The study of Ohio residents of a PFOA-contaminated
water district examined both absolute eosinophil count
and percentage of eosinophils among white blood cells,
and found no significant association of serum PFOA
levels with either outcome in unadjusted analyses
(regression coefficient for absolute eosinophils
¼ 0.00000252 [units not reported], ¼ 0.00, p¼ 0.90;
coefficient for percent eosinophils¼ –0.0000652,
¼ 0.01, p¼ 0.82) (Emmett et al. 2006b) (Table 1).
Similarly, the Taiwan case-control study of asthma
reported no significant cross-sectional trend between
serum PFOA or PFOS levels and absolute eosinophil
count among children without asthma (Ptrend¼ 0.224
and 0.445, respectively) (Dong et al. 2013). However,
significant positive trends with both PFOA and PFOS
concentrations (Ptrend ¼50.001 and 0.009, respectively)
were found among asthmatic children. Similar patterns
of association, with positive trends in asthmatic but not
in non-asthmatic children, were also observed with
serum eosinophil cationic protein levels in the latter
study. Taken together, these two studies suggest no
apparent effect of PFOA or PFOS on eosinophil count in
non-asthmatic individuals at a single time point. Given
the cross-sectional nature of the Taiwan study, the
temporal directionality of the observed associations in
children with asthma is unclear.
C-reactive protein
In the two cross-sectional studies that examined
C-reactive protein levels as an outcome (Table 1), no
significant association with occupational PFOA exposure
was detected among Italian chemical plant workers
(regression coefficient¼ –0.020mg/L per 1000 ng/mL
PFOA, 95% CI¼ –0.268, 0.228) (Costa et al. 2009). No
significant association with either PFOA or PFOS was
found in a cross-sectional study of 287 adolescents and
young adults with or without hypertension in Taiwan
(Ptrend ¼ 0.932 and 0.957, respectively) (Lin et al. 2011).
Limitations include the cross-sectional study design, the
single exposure and outcome measures for a biomarker
that fluctuates within individuals, the lack of quantitative
exposure assessment in the former study (Costa et al.
2009), and participation rates of 10% and 49% for
normotensive and hypertensive subjects, respectively, in
the latter study (Lin et al. 2011). Even so, these
statistically null results do not suggest any substantial
impact of PFOA or PFOS on C-reactive protein levels.
Gene expression
In a prospective birth cohort study set in Norway,
perinatal maternal plasma levels of PFOA, PFOS, and two
other PFASs (perfluorononanoate and perfluorohexane
sulfonate) from 66 women were analyzed in relation to
expression levels of 19 595 unique genes based on
microarrays (Pennings et al. 2015). Gene expression
levels were also analyzed with respect to mother-re-
ported episodes of common cold up to age 3 years
(n¼ 73 children) and post-vaccination anti-rubella anti-
body titers at 3 years (n¼ 58 children) – two immune-
related outcomes that previously were found to be
associated with PFAS levels in the same cohort (Granum
et al. 2013). Expression levels of 453 genes were
significantly (P50.05) positively correlated with PFOA
levels and 490 genes were inversely correlated; 636
genes were positively correlated with PFOS levels and
671 were inversely correlated; 294 genes were positively
correlated with levels of at least two PFASs and 284 were
inversely correlated; 330 genes were positively corre-
lated with common cold episodes and 250 were
inversely correlated; and 522 genes were positively
correlated with anti-rubella antibody titers and 709 were
inversely correlated. Expression levels of 27 genes –
including 3 related to immunological and/or hemato-
poietic functions and 6 involved in development and/or
morphogenesis – were associated with both PFAS levels
and common cold episodes, while 26 genes – including
2 involved in regulation of T-cell activation, 1 other
associated with immunological functionality, and 7
involved in development and/or morphogenesis –
were associated with both PFAS levels and anti-rubella
antibody titers. The authors interpreted these results as
providing a mechanistic link between prenatal PFAS
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exposure and impaired immune function in early child-
hood. However, the interpretation is not clear-cut,
especially given that expression levels of hundreds of
immune-related genes were not correlated with the
exposure or outcomes. Moreover, the small number of
subjects and the large number of comparisons raise
concerns about a large number of false-positive findings;
thus, independent confirmation and targeted mechan-
istic studies are needed to substantiate these results.
Other biomarkers
Other studies of immune biomarkers, which included
counts and percentages of lymphocytes, basophils,
neutrophils, and monocytes (Emmett et al. 2006b), IgA,
IgG, IgM, a1 globulins, a2 globulins, b globulins, and
g globulins (Costa et al. 2009), early-childhood specific
IgE levels against a variety of common food and inhalant
allergens (Granum et al. 2013), and cord plasma levels of
thymic stromal lymphopoietin and interleukin-33
(Ashley-Martin et al. 2015), found few statistically
significant associations. These were a ‘‘very weak’’
positive correlation (¼ 0.13, p¼ 0.01) between PFOA
and absolute monocyte count (but no significant
difference in PFOA levels between subjects with
normal and abnormal monocyte counts), significantly
lower serum PFOA levels in those with abnormal
percentages of lymphocytes (n¼ 18; p¼ 0.01) or neu-
trophils (n¼ 35; p¼ 0.02) (Emmett et al. 2006b), and a
positive association between serum PFOA and a2
globulin levels (regression coefficient¼ 0.026, 95%
CI¼ 0.007, 0.045, but no significant difference in a2
globulin levels between PFOA-exposed and non-
exposed workers) (Costa et al. 2009). Otherwise, reported
associations were statistically non-significant. Given
many of the methodological limitations identified
above [e.g. cross-sectional design, probable confound-
ing, and selection bias in Emmett et al. (2006b), lack of
quantitative exposure assessment in Costa et al. (2009)],
these isolated, as-yet unreplicated results do not
establish any association of PFOA or PFOS with
biomarkers of adverse immune function.
Atopic conditions
Ten studies investigated associations between PFOA
and/or PFOS exposure and the occurrence of specific or
overall atopic or allergic disorders, including seven
studies of asthma (Anderson-Mahoney et al. 2008;
Dong et al. 2013; Granum et al. 2013; Humblet et al.
2014; Leonard et al. 2008; Smit et al. 2015; Steenland
et al. 2015), five studies of wheezing (Granum et al. 2013;
Humblet et al. 2014; Okada et al. 2012, 2014; Smit et al.
2015), four studies of eczema (Granum et al. 2013; Okada
et al. 2012, 2014; Smit et al. 2015), two studies of food
allergy (Granum et al. 2013; Okada et al. 2012), and one
study each of combined allergic disorders (Okada et al.
2014) and atopic dermatitis (Table 2) (Wang et al. 2011).
Five studies were prospective birth cohort studies in
which maternal prenatal or perinatal PFOA and PFOS
levels were measured and parent-reported questionnaire
data were later collected on early childhood health
conditions (Granum et al. 2013; Okada et al. 2012, 2014;
Smit et al. 2015; Wang et al. 2011). Two cohort studies
were conducted at a West Virginia polymer manufactur-
ing plant; one was a retrospective cohort study that
compared mortality between plant workers and general
populations or other regional workers (Leonard et al.
2008), and the other was a cohort study that analyzed
estimated cumulative serum PFOA levels in relation to
validated self-reported asthma that occurred before or
after study entry (Steenland et al. 2015). Another study
used a case-control design to compare serum PFOA and
PFOS levels between children with physician-diagnosed
asthma and children from the same region without a
personal or family history of asthma (Dong et al. 2013).
Finally, two were cross-sectional studies, including one
that used serum PFOA and PFOS measurements and self-
reported data on asthma and wheezing in a representa-
tive group of U.S. adolescents (Humblet et al. 2014), and
another that collected self-reported health information
during in-person group sessions or telephone interviews
with members of a class action lawsuit involving PFOA
contamination of drinking water in the Mid-Ohio Valley
community of Ohio and West Virginia (Anderson-
Mahoney et al. 2008).
Asthma
This last study (Anderson-Mahoney et al. 2008) was
severely methodologically limited by the low participa-
tion rate (2.5%), the lack of an appropriate comparison
population, the failure to control for confounders other
than age and sex, the absence of quantitative exposure
data, the lack of validation of self-reported health
conditions, and the absence of blinding to PFOA
exposure status. Therefore, its finding of an 82% higher
(95% CI¼ 47%, 125%) prevalence of asthma among 566
participants compared with representative adults in the
2001–2002 U.S. National Health and Nutrition Examina-
tion Survey (NHANES) (Table 2) cannot be interpreted in
terms of causality.
The other cross-sectional analysis focused on NHANES
data for adolescents from 1999–2008 (Humblet et al.
2014), and found in some statistical models that a two-
fold increase in serum PFOA concentration was
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associated with a significantly higher odds of ever
having been diagnosed with asthma, based on self-
report (OR¼ 1.18, 95% CI¼ 1.01, 1.39). However, this
association was attenuated and statistically non-signifi-
cant in other models (e.g. OR for doubling in serum
PFOA¼ 1.11, 95% CI¼ 0.87, 1.42 after using sample
weights to account for the probability of selection,
nonresponse adjustment, and adjustment to indepen-
dent population controls; OR for highest versus lowest
tertile of serum PFOA¼ 1.11, 95% CI¼ 0.94, 1.31). Serum
PFOA was not significantly associated with current
asthma, and serum PFOS was not significantly associated
with ever or current asthma. Inference based on these
findings is constrained by the single cross-sectional
assessment of exposures and outcomes and the lack of
validated outcome data.
The cohort mortality study of 6027 workers ever
employed at the polymer manufacturing plant between
1948 and 2002 reported no deaths from asthma,
compared with 2.1 deaths expected in the U.S. popula-
tion, 1.8 deaths expected in the West Virginia popula-
tion, and 0.7 deaths expected in other regional workers
for the same company (Leonard et al. 2008). However,
mortality data are not sensitive for studying risk factors
for the onset or exacerbation of asthma, which is seldom
fatal, and the study was based on small numbers of
expected deaths.
Based on post-diagnosis serum PFOA and PFOS levels
in 231 asthma cases and 225 controls, the Taiwan case-
control study detected a significant positive association
and exposure-response trend between both PFOA and
PFOS and recently diagnosed asthma (OR for top versus
bottom quartile of serum PFOA¼ 4.05, 95% CI¼ 2.21,
7.42, Ptrend 50.001; OR for top versus bottom quartile of
serum PFOS¼ 2.63, 95% CI¼ 1.48, 4.69, Ptrend ¼ 0.003)
(Dong et al. 2013). In case-only analyses, neither
exposure was significantly related to asthma control
(based on a five-item questionnaire about asthma
symptoms, use of rescue medication, and limitation of
daily activities) in the four weeks prior to the study.
PFOA was not significantly related to asthma severity,
but a significant positive association was observed
between PFOS levels and asthma severity (Ptrend
¼ 0.045). Causal inference in this study is limited by
the retrospective exposure assessment after asthma
onset in cases. Moreover, selection bias may have
influenced the findings to an unknown extent because
hospital-based cases and school-based controls were
drawn from different source populations (the authors
did not state whether the cases attended the same
schools as the controls) with potentially different serum
PFOA and PFOS concentrations. Selection bias could also
have occurred if exposure levels differed between study
participants and nonparticipants; the response rate
among potential controls contacted by phone was
72%, not accounting for those who could not be
contacted (response rate among cases not stated). On
the other hand, this study, unlike any others reviewed, is
strengthened by the ascertainment of cases with
validated, physician-diagnosed asthma.
In a prospective birth cohort study of asthma onset,
no significant association was detected between mater-
nal perinatal plasma PFOA or PFOS levels and asthma
incidence, based on 11 cases in the first three years of
childhood for 76 Norwegian mother–child pairs with
available questionnaire data (OR per 1 ng/mL
PFOA¼ 3.56, 95% CI¼ 0.84, 15.02; OR per 1 ng/mL
PFOS¼ 1.22, 95% CI¼ 0.89, 1.66) (Granum et al. 2013).
The small size of this study gave it limited power to
detect any association.
However, a substantially larger prospective birth
cohort study, based on 1024 mother–child pairs from
Greenland and Ukraine, also found no significant
association between maternal prenatal serum PFOA or
PFOS levels and the incidence of asthma in children
aged 5–9 years (Smit et al. 2015). In analyses including
70 children who had ever been diagnosed with asthma,
the OR per 1-standard-deviation increase in PFOA was
0.80 (95% CI¼ 0.62, 1.04) in subjects from both countries
combined, and the OR per 1-standard-deviation increase
in PFOS was 0.86 (95% CI¼ 0.67, 1.10). The authors
conducted a principal component analysis to identify
distinct patterns of exposure to 16 environmental
contaminants, and found no significant associations
with asthma for either of the two principal components
with high loadings for PFOA or PFOS (data not shown in
Table 2). Limitations of this study include its one-time
prenatal measurement of PFOA and PFOS levels, the
reliance on self-reported information on asthma, and the
lack of control for confounders in the analyses of PFOA
and PFOS as single exposures. However, the study is
strengthened by its prospective exposure assessment
and relatively large size.
At the same polymer manufacturing plant as that
studied by Leonard et al. (2008), 3713 workers (or their
next of kin, for 6%) were interviewed regarding their
health history and provided sufficient data for computa-
tion of retrospective estimates of PFOA exposure,
making them eligible for an analysis of several diseases
including asthma (Steenland et al. 2015). Historical
annual serum PFOA levels from occupational exposure
since 1951 were estimated using a job-exposure matrix,
and historical annual serum PFOA levels from environ-
mental exposure since 1951 were estimated based on a
multistage modeling procedure that incorporated an
environmental fate and transport model, information
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about residential history and drinking water sources and
consumption, and a pharmacokinetic model. Subjects
who reported having asthma currently treated with
medication were asked to give consent for medical
records review; of 138 self-reported cases, 108 (78%) had
a medical record reviewed and 84 of those (78%) were
confirmed as asthma, with 82 included in the analysis. A
borderline significant inverse trend was detected
between increasing quartiles of cumulative serum
PFOA and risk of currently treated asthma in unlagged
analyses (OR for top versus bottom quartile¼ 0.53, 95%
CI¼ 0.16, 1.69, Ptrend ¼ 0.27 for continuous log PFOA,
Ptrend ¼ 0.05 for categorical PFOA), and no significant
association was detected in analyses with a 10-year lag
(OR for top versus bottom quartile¼ 0.52, 95% CI¼ 0.09,
2.84, Ptrend ¼ 0.53 for continuous log PFOA, Ptrend ¼ 0.17
for categorical PFOA). Although PFOA exposure in this
study was modeled rather than measured, with an
unknown degree of misclassification, it has the advan-
tage of accounting for changes in exposure over time.
Self-reported outcomes were validated, but only for
positive (not negative) self-reports and not for subjects
whose medical records were not retrieved.
Overall, given the conflicting findings, the temporal
ambiguity of exposure and outcome assessment in most
studies, potential misclassification of self-reported
asthma in several studies, and the greater weight
accorded to the Norway and Greenland/Ukraine studies
due to their prospective design and direct measurement
of prenatal exposures, these studies collectively do not
indicate a causal relationship between PFOA or PFOS
exposure and asthma risk.
Eczema and wheezing
Associations with eczema and wheezing were investi-
gated in four prospective birth cohort studies (Table 2)
(Granum et al. 2013; Okada et al. 2012, 2014; Smit et al.
2015), and wheezing was also examined in the cross-
sectional analysis of 1999–2008 NHANES data (Humblet
et al. 2014). In the latter study, whose limitations were
discussed earlier, no significant associations were
detected between serum PFOA or PFOS concentrations
and self-reported wheezing in the last 12 months (OR
per two-fold increase in PFOA¼ 1.00, 95% CI¼ 0.80,
1.23; OR per two-fold increase in PFOS¼ 0.83, 95%
CI¼ 0.67, 1.02).
In the Norwegian birth cohort (Granum et al. 2013), no
significant association was detected between maternal
perinatal plasma PFOA or PFOS levels and the onset of
parent-reported doctor-diagnosed atopic eczema
(n¼ 14 cases) or eczema and itchiness in the face or at
joints (n¼ 32 cases) during the first three years of
childhood (OR for atopic eczema per 1 ng/mL
PFOA¼ 1.31, 95% CI¼ 0.37, 4.68; OR per 1 ng/mL
PFOS¼ 0.96, 95% CI¼ 0.73, 1.27). The Norwegian study
also did not detect a significant association of maternal
PFOA or PFOS levels with eczema and itchiness in the
third year of life (n¼ 21 cases, 16 with blood specimens),
nor did it find a significant association with the
onset of wheezing during the first three years (n¼ 29
cases) or in the third year of childhood (n¼ 18 cases, 11
with blood).
No significant association between maternal prenatal
serum PFOA or PFOS and childhood eczema (n¼ 37
cases) was reported with follow-up through age
18 months in the prospective cohort of 343 mother–
child pairs in the city of Sapporo, Japan (OR per 10-fold
increase in PFOA¼ 0.96, 95% CI¼ 0.23, 4.02; OR per
10-fold increase in PFOS¼ 0.87, 95% CI¼ 0.15, 5.08)
(Okada et al. 2012). In a substantially larger cohort
including 2062 mother–child pairs throughout Hokkaido
Prefecture, Japan (which includes Sapporo; however, the
cohorts appear not to overlap (Kishi et al. 2013)), no
significant positive association was again observed
between maternal prenatal plasma PFOS and the onset
of childhood eczema through 12 months or 24 months
of age (n¼ 367 cases) (Okada et al. 2014). Instead, a
significant inverse exposure-response trend was
detected with PFOA (Ptrend¼ 0.025), as eczema risk at
24 months was 38% lower (95% CI¼ 0%, 49%) in the top
quartile than the bottom quartile of maternal prenatal
plasma PFOA. Neither of the Japanese cohorts detected
a significant association between maternal prenatal
PFOA or PFOS levels and the onset of wheezing in the
first 18 months (n¼ 33 cases) (Okada et al. 2012) or 12 or
24 months of life (n¼ 397 cases) (Okada et al. 2014).
The Greenland/Ukraine birth cohort study found no
significant association between maternal prenatal serum
PFOA or PFOS and current eczema (n¼ 74 cases), ever
eczema (n¼ 132 cases), current wheeze (n¼ 130 cases),
or ever wheeze (n¼ 43 cases) at ages 5–9 years in the
majority of comparisons, which included separate
analyses of subjects from Greenland and Ukraine and
pooled analyses of all subjects (i.e. 24 odds ratios for two
exposures, four outcomes, and three country groups)
(Smit et al. 2015). For example, the ORs in association
with a 1-standard-deviation increase in exposure in the
combined Greenland/Ukraine subjects were 0.97 (95%
CI¼ 0.81, 1.17) for PFOA and ever eczema, 0.98
(95% CI¼ 0.82, 1.18) for PFOS and ever eczema, 0.91
(95% CI¼ 0.76, 1.10) for PFOA and ever wheeze, and 0.83
(95% CI¼ 0.69, 1.00) for PFOS and ever wheeze. The only
statistically significant association was an inverse (i.e.
protective) association between a 1-standard-deviation
increase in maternal prenatal PFOS and risk of current
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wheeze in Ukrainian subjects (OR¼ 0.60, 95% CI¼ 0.38,
0.92). Associations between principal components
heavily loaded with PFOS or PFOA were also generally
statistically null, with only a single statistically significant
inverse association between the principal component
with high factor loadings for PFOA, PFOS, and perfluor-
oheptanoic acid and risk of current wheeze (data not
shown in Table 2).
Overall, despite being constrained by the lack of
repeated exposure assessment and modest case num-
bers, the four birth cohort studies suggest no significant
adverse impact of prenatal PFOA or PFOS exposure on
the onset of eczema or wheezing in early childhood, and
the cross-sectional study indicates no apparent associa-
tion between PFOA or PFOS exposure and the
prevalence of wheezing in adolescence.
Food allergy
In the Sapporo birth cohort, no significant association
was observed between maternal prenatal serum PFOA
or PFOS and the development of food allergy during the
first 18 months of life (OR per 10-fold increase in
PFOA¼ 1.67, 95% CI¼ 0.52, 5.37; OR per 10-fold increase
in PFOS¼ 3.72, 95% CI¼ 0.81, 17.10) (Table 2) (Okada
et al. 2012). Likewise, as mentioned earlier in the section
on immune biomarkers, the Norwegian prospective birth
cohort study found no significant associations of
maternal PFOA and PFOS levels at delivery with child
sensitization to a variety of food and inhalant allergens
at age 3 years, based on allergen-specific IgE levels
(Table 1) (Granum et al. 2013). Taken together, these
studies provide no evidence for a causal relationship
between early-life PFOA or PFOS exposure and the
development of food allergy in childhood.
Other atopic conditions
Other atopic health conditions were assessed by only
one study each, and thus lack sufficient evidence to
assess consistency across studies. In the Hokkaido birth
cohort study, no association with total allergic diseases
(including eczema, wheezing, and allergic rhinoconjunc-
tivitis symptoms as of age 24 months) was observed for
maternal prenatal plasma PFOS levels (Okada et al.
2014). For maternal PFOA levels, no association was
observed among boys, but a significant inverse trend
was detected among girls (Ptrend ¼ 0.017; OR for top
versus bottom quartile¼ 0.64, 95% CI¼ 0.42, 0.97) and
in all children combined (Ptrend¼ 0.030; OR¼ 0.79, 95%
CI¼ 0.59, 1.04). The single study of atopic dermatitis, a
prospective birth cohort study of 244 mother–child pairs
in Taiwan, found no significant association in adjusted
models relating cord serum PFOA or PFOS levels to the
onset of atopic dermatitis by age 2 years, based on
43 cases classified using questionnaire data (Table 2)
(Wang et al. 2011). Overall, despite their reliance on
unvalidated parent-reported outcomes and use of a
single exposure measurement per subject, these studies
suggest no apparent relationship between pre- or
perinatal PFOA or PFOS levels and risk of various
atopic disorders in early life.
Infectious diseases
Five studies (Fei et al. 2010; Granum et al. 2013; Leonard
et al. 2008; Looker et al. 2014; Okada et al. 2012)
reported on PFOA or PFOS levels in relation to infectious
diseases (Table 3). Two of these studies evaluated the
occurrence of common colds (Granum et al. 2013;
Looker et al. 2014), two evaluated the occurrence of
otitis media (Granum et al. 2013; Okada et al. 2012), and
two examined all infectious and parasitic diseases
combined (Fei et al. 2010; Leonard et al. 2008), while
other infectious diseases were evaluated by only one
study each. Two studies used registry-based hospitaliza-
tion or mortality data on infectious diseases (Fei et al.
2010; Leonard et al. 2008), whereas the rest used parent-
or self-reported health outcomes. Three studies pro-
spectively followed mother–child pairs from birth to age
8.2 years (on average) (Fei et al. 2010), 3 years (Granum
et al. 2013), and 18 months (Okada et al. 2012),
respectively; one was a retrospective cohort mortality
study of workers at a West Virginia polymer production
plant that used PFOA (Leonard et al. 2008); and the
remaining study was a cross-sectional analysis of adults
exposed to a PFOA-contaminated public water supply in
the Mid-Ohio Valley of Ohio and West Virginia
(Looker et al. 2014).
Common cold
The prospective birth cohort study of mother–child pairs
in Norway, described earlier, found significant positive
associations between a 1-ng/mL increase in maternal
perinatal plasma PFOA and number of episodes of the
common cold in the first three years of life as well as
during the third year, with regression coefficients of 0.42
in both multivariate models (95% CI¼ 0.21, 0.62 and
0.16, 0.72, respectively) (Table 3) (Granum et al. 2013). No
significant association was detected between maternal
perinatal plasma PFOA and the incidence of any
common cold (yes versus no) in the third year (n¼ 70
positive reports among 85 children). For maternal PFOS
levels, no significant association was detected with
number of cold episodes in the first three years or the
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third year of life, or with the incidence of any common
cold in the third year.
In the cross-sectional study of 755 adults in the Mid-
Ohio Valley, neither PFOA nor PFOS levels in serum were
significantly associated with the presence of any cold
(reported by 538 subjects) or the number of cold
episodes in the last 12 months (Looker et al. 2014).
The OR for any cold per 1 log10 ng/mL PFOA was 0.83
(95% CI¼ 0.61, 1.13) and that for PFOS was 0.83 (0.51,
1.34) (Table 3). These study subjects were a selected
subgroup of 69 030 participants in the C8 Health Project,
a study of individuals who had lived, worked, or
attended school for at least 12 months in one of six
public water districts contaminated with PFOA from a
nearby polymer manufacturing plant (Frisbee et al.
2009). Methodological limitations include the cross-
sectional exposure and outcome assessment, the poten-
tial for selection bias, and possible confounding by risk
factors other than age and sex (the only adjusted
covariates). Overall, these findings provide inconsistent
evidence regarding a potential effect of PFOA exposure
on the frequency of common cold episodes, and they
suggest no significant association with PFOS exposure.
Otitis media
Childhood otitis media (middle ear infection) was
investigated with respect to maternal prenatal and
perinatal PFOA and PFOS levels in two prospective
birth cohort studies based on 343 mother–child pairs in
Sapporo, Japan, followed to age 18 months (n¼ 61
cases) (Okada et al. 2012) and up to 85 mother–child
pairs in Norway followed to age 3 years (n¼ 27 cases in
all three years) (Granum et al. 2013), respectively
(Table 3). Neither study reported a significant association
with PFOA or PFOS exposure. The OR per 10-fold
increase in PFOA was 1.51 (95% CI¼ 0.45, 5.12) and
that for PFOS was 1.40 (95% CI¼ 0.33, 6.00) in the
Japanese study, while the OR per 1 ng/mL PFOA for all
three years was 0.76 (95% CI = 0.81, 1.29) and that for
PFOS was 1.02 (95% CI = 0.81, 1.29) in the Norwegian
study. Despite their limitations, discussed earlier, these
studies provide no solid evidence of an effect of PFOA or
PFOS on otitis media in young children.
Other infections
One of the two registry-linkage studies that evaluated
all infectious and parasitic diseases combined was the
occupational cohort mortality study, in which PFOA-
exposed workers experienced significantly fewer
deaths from infectious and parasitic diseases (one
death observed) than expected in the general U.S.
population (15.0 deaths expected), but no significant
difference compared with the general West Virginia
population (3.4 deaths expected) or the regional
worker population (1.1 deaths expected) (Table 3)
(Leonard et al. 2008).
The other study involved the linkage of a cohort of
1400 mother–child pairs with the national hospital
discharge registry in Denmark, yielding 577 hospitaliza-
tions for infectious diseases (including all infectious and
parasitic diseases plus additional organ-specific infec-
tions) among 363 children followed prospectively from
birth to 5.8–10.7 years (mean¼ 8.2 years) (Fei et al.
2010). In this cohort, maternal first-trimester plasma
PFOA and PFOS levels were not significantly associated
with increased risk of infectious disease hospitalization
for boys and girls combined, with consistently statisti-
cally null findings across strata of age group and birth
order. The only statistically significant association overall
was an inverse association between the second versus
first quartile of maternal PFOA and risk of infectious
disease hospitalization. Significant positive associations
of both exposures with infectious disease hospitalization
were observed among girls (per-quartile RR for
PFOA¼ 1.21, 95% CI¼ 1.04, 1.42; per-quartile RR for
PFOS¼ 1.18, 95% CI¼ 1.03, 1.36). Among boys, however,
the opposite was true, with a significant inverse
association between maternal PFOA and hospitaliz-
ation for infectious disease (per-quartile RR¼ 0.83,
95% CI¼ 0.73, 0.95) but no significant association for
maternal PFOS (per-quartile RR¼ 0.90, 95% CI¼ 0.80,
1.02).
This study is strengthened by the use of validated,
objectively recorded outcome data and prospectively
collected exposure data, although infectious diseases
requiring hospitalization represent only a subset of all
infections. The analysis of infectious and parasitic disease
deaths in the occupational cohort study included an
even smaller subset of all infections, and was further
limited by the implicit assumption that all workers were
equally exposed to PFOA (Leonard et al. 2008). In the
absence of a biologically plausible explanation for
opposite effects by sex, the results of these two studies
collectively do not suggest a consistent or convincing
association between PFOA or PFOS and serious infec-
tious diseases leading to death or hospitalization.
Infectious diseases examined in single studies were
mortality from influenza and pneumonia, ‘‘flu’’ infec-
tion, and gastroenteritis (Table 3). In the West Virginia
worker cohort, significantly fewer deaths from influ-
enza and pneumonia were observed (14 deaths) than
expected in the general U.S. population (26.5 deaths
expected) and the general West Virginia population
(28.2 deaths expected), with no significant difference
CRITICAL REVIEWS IN TOXICOLOGY 319
from expectation in the regional worker population
(15.7 deaths expected) (Leonard et al. 2008). In the
cross-sectional study of Mid-Ohio Valley adults, the
occurrence of any ‘‘flu’’ infection in the last 12 months
(self-reported by 163 of 755 subjects) was not
significantly associated with serum PFOA or PFOS
levels, nor was the occurrence of any cold or ‘‘flu’’
infection significantly associated with either exposure
(OR per 1 log10 ng/mL PFOA¼ 0.85, 95% CI¼ 0.62,
1.16; OR per 1 log10 ng/mL PFOS¼ 0.90, 95% CI¼ 0.55,
1.48) (Looker et al. 2014). The Norwegian cohort study
reported a marginally significant positive association
between a 1-ng/mL increase in maternal perinatal
plasma PFOA concentration and parent-reported
number of episodes of gastroenteritis in the third
year (coefficient¼ 0.31, 95% CI¼ 0.002, 0.61), but no
significant association with number of gastroenteritis
episodes in the first three years or the presence versus
absence of gastroenteritis in years 1–3 or 3 (Granum
et al. 2013). Maternal PFOS levels also were not
significantly associated with any measure of gastro-
enteritis. Collectively, in light of the equivocal findings
and the methodological limitations discussed earlier,
these studies do not offer consistent evidence to
support any effect of PFOA or PFOS on the occurrence
of infectious diseases, and the few significant
results (in either direction) could have occurred by
chance.
Vaccine response
Four studies, including two prospective birth cohort
studies (Grandjean et al. 2012; Granum et al. 2013) and
two cross-sectional studies of adults (Kielsen et al. 2015;
Looker et al. 2014), investigated whether PFOA and PFOS
levels are related to antibody response to common
vaccines (Table 4). The first of these was a study of 587
Faroe Islands children from birth through age 5 years
(before and after immunization with the diphtheria and
tetanus booster vaccine) up to age 7 years, with
exposure information on serum PFOA and PFOS levels
in mothers during the third trimester of pregnancy and
in children at age 5 years prior to receiving the booster
(Grandjean et al. 2012). Of the 587 children, 460 (78%)
participated in both the 5-year and 7-year examinations,
and 431 (73%) had complete data with serum analyses.
Vaccine antibody titers prior to the five-year booster,
four weeks after the five-year booster, and at age 7 years
(with or without adjustment for antibody titer at age
5 years) were analyzed in terms of percentage difference
in concentration, as well as in terms of the percentage
with insufficient antibody concentration for seroprotec-
tion (0.1 IU/mL).
Maternal prenatal serum PFOA and PFOS levels
generally were not associated with a significant differ-
ence in the tetanus vaccine response, other than a
significant positive association between higher maternal
PFOS and higher anti-tetanus toxoid antibody titer at
age 7 years, adjusted for titer at age 5 years (Table 4).
Maternal PFOA and PFOS levels were generally asso-
ciated with a poorer childhood diphtheria vaccine
response, as measured based on antibody titers and
the presence of a non-protective antibody level,
although most differences were statistically non-signifi-
cant. Several significant associations were observed
between child serum PFOA level at age 5 years and
poorer antibody response to both tetanus and
diphtheria vaccines at age 7 years, but not at age 5
years. For example, the OR for inadequate anti-tetanus
toxoid antibody concentration at age 7 per two-fold
increase in PFOA at age 5 was 4.20 (95% CI¼ 1.54, 11.44),
and that for anti-diphtheria toxoid antibody was 3.27
(95% CI¼ 1.43, 7.51). For PFOS, child serum levels at age
5 years were consistently, although mostly non-signifi-
cantly, associated with indicators of poorer antibody
response to the tetanus and diphtheria vaccines at ages
5 and 7 years. For example, the OR for inadequate anti-
tetanus toxoid antibody concentration at age 7 per two-
fold increase in PFOA at age 5 was 2.61 (95% CI¼ 0.77,
8.92), and that for anti-diphtheria toxoid antibody was
2.38 (95% CI¼ 0.89, 6.35). When PFOS isomers were
separately classified as linear or branched, estimated
associations with child PFOS levels did not differ
substantially by isomer, whereas associations with
maternal PFOS levels were similar between linear and
total PFOS but attenuated for branched PFOS.
The second study of vaccine response was the
Norwegian birth cohort study, which collected outcome
information on antibody titers against four vaccine
antigens at age 3 years among children who followed
the standard national childhood vaccination program
(n¼ 49–51 subjects with outcome data, depending on
the vaccine type) (Table 4) (Granum et al. 2013).
Although 1-ng/mL increases in maternal perinatal
plasma PFOA and PFOS levels were associated with
significantly lower anti-rubella antibody levels at age
3 years (PFOA coefficient¼ –0.49 optical density units,
95% CI¼ –0.64, –0.17; PFOS coefficient¼ –0.08, 95%
CI¼ –0.14, –0.02), no significant association was
detected with antibody levels against measles virus,
Haemophilus influenza type b, or tetanus toxoid.
The third study of vaccine response was a cross-
sectional analysis of 403 Mid-Ohio Valley adults who
participated in the C8 Health Project and subsequently
completed a second interview and blood study.
Information was collected on influenza-specific antibody
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levels before and three weeks after immunization with a
trivalent influenza vaccine (Table 4) (Looker et al. 2014).
Vaccine responses against influenza type A/H1N1, type
A/H3N2, and type B were evaluated in several ways:
increase in titer after vaccination, log10-transformed
increase in titer after vaccination, log10-transformed
ratio of postvaccine to prevaccine antibody titer,
seroconversion (defined as a four-fold or greater rise in
postvaccination titer), and seroprotection (defined as
postvaccination hemagglutination inhibition titer41:40).
Serum PFOA and PFOS levels were analyzed as quartiles
and as log10-transformed continuous variables. In addi-
tion, results were reported for all subjects combined and
after stratification by patient demographic characteris-
tics, comorbidities, or medication use – at least 18
stratification factors in total. Therefore, the interpretation
of results must be considered in light of the fact that
hundreds of hypotheses were tested and numerous
statistically significant findings would be expected to
arise by chance.
In general, no clear pattern emerged between serum
PFOA or PFOS level and postvaccination rise in
geometric mean titer of antibodies against any of the
three influenza strains, other than a significantly lower
anti-influenza type B antibody GMT in the top quartile of
PFOA concentration (Table 4) (Looker et al. 2014). When
antibody titer increases and ratios were log10-trans-
formed, nearly all multivariate adjusted associations
were also statistically non-significant, except for scat-
tered inverse associations, with no clear negative
exposure-response trend, between serum PFOA level
and log10-transformed antibody titer rise and ratio for
anti-influenza A/H3N2. No significant associations were
detected between PFOA or PFOS and seroconversion
against any of the three influenza strains. When
seroprotection was examined as the outcome, serum
PFOA level was inversely associated with the prevalence
of seroprotection against influenza A/H3N2, with a
marginally significant exposure-response trend (Ptrend
¼ 0.07; OR for top versus bottom quartile of
PFOA¼ 0.39, 95% CI¼ 0.15, 0.99), but an opposite
trend toward a higher prevalence of seroprotection
was observed for influenza A/H1N1 (Ptrend ¼ 0.02; OR for
top versus bottom quartile of PFOA¼ 6.47, 95%
CI¼ 0.91, 45.85).
Most recently, a small study of 12 healthy, previously
immunized adult volunteers in Denmark measured anti-
diphtheria and anti-tetanus toxoid antibody titers at the
time of diphtheria and tetanus booster vaccination and
at 2, 4, 7, 10, 14, and 30 days after vaccination to
document the pattern of antibody response (Table 4)
(Kielsen et al. 2015). The key time interval of antibody
titer change was 4 to 10 days after vaccination, and
serum levels of PFOA, PFOS, and six other PFASs were
measured on post-vaccination day 10; thus, this study
was cross-sectional in design. Associations were esti-
mated as the log-linear relationship between serum
PFAS levels and percentage change in anti-diphtheria
and anti-tetanus toxoid antibody titers from days 4 to 10,
with PFAS and antibody concentrations modeled on the
log10 scale. A significant inverse association was
detected between a doubling in serum PFOS concentra-
tion and percentage change in anti-diphtheria toxoid
antibody titer (11.90%, 95% CI¼21.92%,0.33%).
Otherwise, no significant association was detected
between a doubling in serum PFOS concentration and
percentage change in anti-tetanus toxoid antibody titer
(-3.59%, 95% CI¼ -11.91%, 5.51%) or between a dou-
bling in serum PFOA concentration and either outcome
(diphtheria:8.22%, 95% CI¼20.85%, 6.44%; tetanus:
0.23%, 95% CI¼10.40%, 12.1%). These results were
not adjusted for any potential confounders, but the
authors stated that models adjusted for age and sex
‘‘showed similar results.’’
As a whole, these four studies (Grandjean et al. 2012;
Granum et al. 2013; Kielsen et al. 2015; Looker et al.
2014) do not provide consistent evidence of a significant
association between PFOA or PFOS exposure and
serological vaccine responses in general. Within each
study, most estimated associations were statistically
non-significant, and results were inconsistent by
vaccine type and by outcome classification. Authors
provided no a priori biological hypothesis to explain
why PFOA or PFOS exposure would impair the
antibody response to one vaccine type but not
another. Some authors suggested that their results
could be explained by different immunostimulatory
effects of different vaccines, but they did not elaborate
on this hypothesis or provide supporting mechanistic
evidence.
Although Grandjean et al. (2012) found fairly con-
sistent – albeit mostly statistically non-significant –
intra-study associations between childhood serum
PFOA and PFOS levels and poorer antibody responses
against tetanus and diphtheria toxoids, associations with
maternal prenatal serum PFOA and PFOS levels were
inconsistent between vaccine types. Two studies were
strengthened by their measurement of PFOA and PFOS
levels prior to ascertaining vaccine response (Grandjean
et al. 2012; Granum et al. 2013) and one had the
additional advantage of collecting exposure and out-
come information at two time points each (Grandjean
et al. 2012). However, the variability in findings by timing
of exposure and outcome measurement in the latter
study (e.g. mostly non-significant associations with
prenatal PFOA and PFOS concentrations, but several
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significant associations between higher PFOA and PFOS
concentrations at age 5 years and poorer vaccine
response at age 7 years) makes the results difficult to
interpret. This pattern of results could reflect a window
of susceptibility in early childhood, but such an
explanation remains conjectural. None of the studies
demonstrated a clinically recognizable increased risk of
infectious diseases as a consequence of a diminished
vaccine response. Overall, although these results are not
sufficient to establish a causal effect of PFOA or PFOS
exposure on an impaired serological vaccine response,
some of the positive associations are striking in
magnitude and require replication in independent
studies.
Autoimmune and inflammatory conditions
Two cross-sectional studies and one mixed retrospec-
tive/prospective cohort study evaluated whether PFOA
and PFOS levels were associated with the prevalence of
self-reported osteoarthritis (Innes et al. 2011; Steenland
et al. 2015; Uhl et al. 2013), two cohort studies with both
retrospective and prospective follow-up evaluated
whether PFOA levels were related to risk of validated
self-reported autoimmune disorders (Steenland et al.
2013, 2015), and one prospective birth cohort study
assessed associations of prenatal or childhood PFOS
levels with autoantibody levels in children (Osuna et al.
2014).
The earlier cross-sectional study of osteoarthritis was
based on 3731 adults with osteoarthritis and 45 701
without osteoarthritis who lived, worked, or attended
school in one of six PFOA-contaminated water districts in
the Mid-Ohio Valley and were enrolled in the C8 Health
Project. Significant positive associations were found
between increasing serum PFOA levels and osteoarthritis
prevalence (Ptrend¼ 0.00001; OR per log-transformed 1-
ng/mL increase in PFOA¼ 1.07, 95% CI¼ 1.04, 11) (Table
5) (Innes et al. 2011). The observed association was
limited to adults under age 55 years (Pinteraction by age
50.00001) and those who were not obese (Pinteraction by
obesity status¼ 0.0005), and was not detected when the
analysis was restricted to serum PFOA levels typical of
the general U.S. population (20 ng/mL). By contrast,
this study found a significant inverse association
between serum PFOS levels and osteoarthritis preva-
lence (Ptrend¼ 0.00001; OR per log-transformed 1-ng/mL
increase in PFOS¼ 0.88, 95% CI¼ 0.84, 0.93) that was not
appreciably altered after stratification by age group or
obesity status, or after restriction to relatively low PFOS
levels.
To follow up on these findings, a cross-sectional study
was conducted using 2003–2008 NHANES data from
3809 adults sampled to be representative of the general
U.S. population, including 365 who reported ever having
been diagnosed with osteoarthritis (Table 5) (Uhl et al.
2013). No significant association was detected between
serum PFOA levels and osteoarthritis prevalence among
men, but among women a positive exposure-response
pattern was detected (OR per log-transformed 1-ng/mL
increase in PFOA¼ 1.35, 95% CI¼ 1.02, 1.79) and risk was
significantly higher in the top quartile of PFOA than the
bottom (OR¼ 1.98, 95% CI¼ 1.24, 3.19). In contrast to
the earlier study, this association was detected only
among obese adults. Findings were also more pro-
nounced among younger (ages 20–49 years) than older
women. Also in contrast to the significant inverse
association with PFOS reported by Innes et al. (2011),
Uhl et al. (2013) reported a positive association (OR per
log-transformed 1-ng/mL increase in PFOS¼ 1.15, 95%
CI¼ 0.94, 1.40; OR for top versus bottom quartile of
PFOS¼ 1.77, 95% CI¼ 1.05, 2.96), again with stronger
associations in women than men and in younger (ages
20–49 years) than older women.
The occupational cohort study of osteoarthritis
included 3713 workers at a West Virginia polymer
plant who self-reported whether they were currently
taking prescription medication for osteoarthritis
(Steenland et al. 2015). No significant association was
observed between estimated cumulative serum PFOA
levels and medicated osteoarthritis (n¼ 196 cases) in
either unlagged analyses (OR for highest versus lowest
quartile¼ 0.97, 95% CI¼ 0.59, 1.59, Ptrend¼ 0.92 for
continuous log PFOA, Ptrend¼ 0.48 for categorical
cumulative PFOA) or 10-year lagged analyses (OR for
highest versus lowest quartile¼ 0.67, 95% CI¼ 0.39,
1.14, Ptrend ¼ 0.13 for continuous log PFOA, Ptrend
¼ 0.15 for categorical cumulative PFOA).
The two cross-sectional studies of osteoarthritis cited
an Australian study in which 81% of ‘‘definite’’ osteoar-
thritis (67/83), 57% of ‘‘possible’’ osteoarthritis (8/14),
and 89% of ‘‘negative’’ osteoarthritis (8/9) self-reported
by adults aged 45–64 years was validated by physical
examination (March et al. 1998). However, the results of
this small study of highly selected adult volunteers may
not be generalizable to other populations; thus, the
validity of self-reported osteoarthritis in these studies
remains unclear. The occupational cohort study
restricted the outcome to osteoarthritis currently treated
with prescription medication with the goal of minimiz-
ing misclassification, but this restriction also limited
osteoarthritis cases to a relatively severe subset of
disease. Taken together, the results of these three
studies (Innes et al. 2011; Steenland et al. 2015; Uhl
et al. 2013) do not demonstrate a consistent association
between serum PFOA or PFOS levels and osteoarthritis.
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Key methodological limitations of the two cross-sec-
tional studies, including the temporal ambiguity of
exposure and outcome, reliance on PFOA and PFOS
measured at a single point in time, absence of
information on timing of osteoarthritis onset, and
probably misclassified outcome data, preclude a causal
interpretation of the observed positive associations and
accord greater weight to the occupational cohort study,
despite its use of estimated exposure levels and a
relatively restrictive case definition.
One study of PFOA exposure and autoimmune
diseases was based on 32 254 adults who were enrolled
in the C8 Health Project or a separate study of workers at
the nearby polymer manufacturing plant, and who
completed a follow-up demographic and medical history
survey that assessed whether respondents had ever
been diagnosed with certain autoimmune diseases
(Table 5) (Steenland et al. 2013). Cumulative PFOA
exposure since 1952 (the year of first PFOA emissions
from the polymer plant) was estimated for each subject
based on the estimated intake of PFOA-contaminated
drinking water, as well as occupational exposure for
plant workers. In retrospective analyses, no significant
associations were detected between estimated PFOA
exposure and lifetime history of Crohn’s disease (95
cases), rheumatoid arthritis (346 cases), insulin-depen-
dent diabetes (160 cases), type I diabetes (85 cases),
lupus (72 cases), or multiple sclerosis (99 cases). A
significant positive association was detected between
estimated PFOA exposure and lifetime history of
ulcerative colitis (151 cases; OR for top versus bottom
quartile with no exposure lag period¼ 2.86, 95%
CI¼ 1.65, 4.96, Ptrend50.0001; OR with 10-year
lag¼ 3.05, 95% CI¼ 1.56, 5.96, Ptrend50.0001).
Estimates were comparable when person-time was
counted from the first year of residence in the study
area or the first year of employment at the plant, or
when estimated background-level exposure to PFOA
was excluded. In prospective analyses, positive but
statistically non-significant ORs were detected between
PFOA levels and incident ulcerative colitis newly
diagnosed between C8 Health Project baseline in
2005–2006 and follow-up in 2008–2011, with no
significant trend (30 cases; unlagged Ptrend¼ 0.21,
lagged Ptrend¼ 0.12), and no significant association was
detected with incident rheumatoid arthritis (56 cases).
No a priori explanation was provided for why PFOA
exposure might be associated with ulcerative colitis but
not other autoimmune disorders.
Validated self-reported autoimmune diseases were
also analyzed separately among the 3713 polymer plant
workers in this cohort study, with results reported for
ulcerative colitis and rheumatoid arthritis (Steenland
et al. 2015). Some evidence of a positive trend was
observed between estimated cumulative serum PFOA
and risk of rheumatoid arthritis with no lag (23 cases; OR
for highest versus lowest quartile¼ 4.45, 95% CI¼ 0.99,
19.9, Ptrend for continuous log PFOA¼ 0.54, Ptrend for
categorical PFOA¼ 0.04), although the association was
attenuated with a 10-year lag (OR¼ 2.62, 95% CI¼ 0.47,
14.7, Ptrend for continuous log PFOA¼ 0.75, Ptrend for
categorical PFOA¼ 0.06). For ulcerative colitis, no
significant association was observed in the unlagged
analysis (28 cases; OR for highest vs. lowest quartile of
estimated cumulative PFOA¼ 2.74, 95% CI¼ 0.78, 9.65,
Ptrend for continuous log PFOA¼ 0.05, Ptrend for catego-
rical PFOA¼ 0.26), but a significant positive association
was observed with a 10-year lag (OR¼ 6.57, 95%
CI¼ 1.47, 29.40, Ptrend for continuous log PFOA¼ 0.05,
Ptrend for categorical PFOA¼ 0.05).
Outcome validation in these studies (Steenland et al.
2013, 2015) was attempted only for positive self-reports.
Approximately one-quarter of combined community
members and workers did not grant consent for
validation, and medical records were not obtained for
approximately 8% of those who consented; among
workers only, 17% of subjects who self-reported disease
did not have medical records available for validation.
Overall, only 34% of self-reported autoimmune disorders
in the combined study and 44% in the occupational
study were validated, and the rest were excluded from
the analysis. Exposure misclassification is also a concern,
given that cumulative PFOA exposure was estimated
based on a model that was validated against measured
serum PFOA levels in 2005–2006 (Spearman’s ¼ 0.67)
(Shin et al. 2011), but serum measurements were not
available in other years. However, exposure and outcome
misclassification, and possibly selection and/or reporting
bias, might be expected to lead to false associations with
multiple autoimmune diseases. Therefore, the positive
association with ulcerative colitis but not with other
autoimmune disorders may not be due to bias alone. The
sizeable, statistically significant ORs and exposure-
response trends for ulcerative colitis in this large cohort
study are noteworthy and require replication in indepen-
dent study settings. Given that all of the subjects in the
occupational study (Steenland et al. 2015) were also
included in the combined study of community members
and workers (Steenland et al. 2013), and the authors did
not report whether the association was detected
separately among community members, these two
studies cannot be considered as mutually independent.
Overall, the results from these studies do not establish an
association between PFOA exposure and risk of any
autoimmune disease, and the results for ulcerative colitis
require independent confirmation.
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A pilot prospective birth cohort study of 38 children in
the Faroe Islands evaluated whether PFOA and PFOS
levels measured in cord blood at birth and in serum at age
7 years were associated with serum concentrations of IgG
and IgM autoantibodies against six neural proteins and
three non-neural proteins in children at age 7 (Osuna
et al. 2014). This study was based on the premise that
increased autoantibodies might indicate tissue damage
(and the subsequent release of self-antigens) following
chemical exposure. Prenatal and age-7 PFOA levels were
not significantly associated with any of the 18 auto-
antibodies measured (2 isotypes each of 9 autoantibo-
dies). For PFOS most associations were also
non-significant, except for a single significant inverse
association between prenatal PFOS levels and anti-actin
IgG levels at age 7 (22% change in autoantibody
concentration per 2-fold increase in cord blood PFOS,
p 0.05). Given the numerous associations tested, the
lack of adjustment for confounders, and the selection of
subjects with available data, this single association –
which would suggest a protective effect against tissue
damage, but which the authors interpreted as potentially
indicating an immunosuppressive effect – could well be a
spurious finding, and its clinical relevance is unclear.
Weight-of-evidence evaluation
The ensuing sections provide an evaluation of the
weight of epidemiologic evidence addressing the causal
question of interest, that is, whether PFOA and PFOS are
causally related to adverse immunological health condi-
tions in humans. This evaluation was conducted using
the framework of the Bradford Hill ‘‘viewpoints’’ (Hill
1965), which consist of strength of association, consis-
tency, temporality, biological gradient, plausibility,
coherence, specificity, experiment, and analogy. As
stated by Sir Austin Bradford Hill, none of these nine
viewpoints can prove or disprove a causal relationship,
and none can be required as essential (except that an
exposure must precede an effect temporally).
Nevertheless, they provide a rational and convenient
framework by which to assess the overall balance of
epidemiologic evidence for or against a causal
hypothesis.
Strength of association
In general, a strong association is less likely than a weak
association to be explained by confounding or bias (Hill
1965). The strength of an association is not straightfor-
ward to evaluate when the exposure and outcome are
analyzed on a continuous scale, for example, as when an
association is reported as the per-unit increase in a
biomarker per 1-ng/mL increase in serum PFOA or PFOS.
Nevertheless, most estimated coefficients for the rela-
tionship between circulating PFOA or PFOS concentra-
tions and immune biomarkers were close to the null
value of zero.
Most relative risk estimates for the association
between increasing PFOA or PFOS exposure (whether
analyzed as exposed versus unexposed, in tertiles or
quartiles, on the log2 or log10 scale, or per unit increase –
scales that are not directly comparable) and atopic,
infectious, and autoimmune and inflammatory disorders
and anti-vaccine antibody seroconversion or seroprotec-
tion were between 0.5 and 2.0. Thus, in general, the
strength of the observed associations does not offer
compelling evidence in favor of a causal interpretation.
Stronger ORs were reported for 10-fold increases in
maternal prenatal serum PFOA and PFOS concentration
and development of food allergy or wheezing in young
Japanese children (Okada et al. 2012), but these
estimates were statistically unstable and non-significant.
ORs above 2.0 were also reported for PFOA or PFOS
exposure in association with asthma (Anderson-
Mahoney et al. 2008; Dong et al. 2013; Granum et al.
2013); with inadequate anti-vaccine antibody concentra-
tions at age 7 years (Grandjean et al. 2012); with
seroprotection against influenza type A/H1N1 (Looker
et al. 2014); and with ulcerative colitis (Steenland et al.
2013, 2015). These ORs warrant greater attention,
although the studies in which they were detected
could not convincingly exclude confounding or bias as
explanations for these results, which also may be due to
chance.
Consistency
Positive associations with only two immune conditions
were detected in at least two independent studies. The
prevalence of self-reported asthma was significantly
positively associated with residence in a PFOA-contami-
nated water district (Anderson-Mahoney et al. 2008) and
with concurrently measured serum PFOA in some but
not all analyses of representative U.S. adolescents
(Humblet et al. 2014). Additionally, risk of incident
asthma was significantly positively associated with PFOA
and PFOS levels in Taiwanese children (Dong et al. 2013).
By contrast, no significant associations between PFOA or
PFOS exposure and risk of asthma were detected in
Norwegian children up to age 3 years (Granum et al.
2013), children from Greenland and Ukraine up to ages
5–9 years (Smit et al. 2015), or PFOA-exposed polymer
production workers (Leonard et al. 2008; Steenland et al.
2015). The methodologically stronger studies in this
group are the Taiwan study with physician-confirmed
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incident asthma (Dong et al. 2013), the European studies
with prospective exposure assessment and follow-up for
asthma development (Granum et al. 2013; Smit et al.
2015), and the occupational cohort study with long-term
cumulative exposure estimates (Steenland et al. 2015),
although these studies still have important methodolo-
gical limitations. Three of the four higher-quality studies
found no significant association between PFOA or PFOS
exposure and asthma risk. Thus, taken together, the
results of these studies do not establish a consistent
positive association between PFOA exposure and risk of
asthma.
Two cross-sectional studies found a significant posi-
tive association between serum PFOA concentration and
the prevalence of self-reported osteoarthritis (Innes et al.
2011; Uhl et al. 2013), whereas one occupational cohort
study found no significant association (Steenland et al.
2015). The positive association was restricted to adults
under 55 years and non-obese subjects in the study of
Mid-Ohio Valley residents (Innes et al. 2011), whereas it
was restricted to women and obese adults in the study
of NHANES participants (Uhl et al. 2013). Thus, the
subgroup-specific results were inconsistent between
studies, as were the reported associations with PFOS,
and no clearly consistent positive association between
PFOA exposure and osteoarthritis risk is demonstrated
by these studies.
Otherwise, no significant positive associations with
any specific outcome (considering antibody responses to
different vaccines as distinct outcomes) were reported in
multiple studies. Instead, consistency across studies was
observed mainly for null results, as detected for white
blood cell count (Costa et al. 2009; Emmett et al. 2006b;
Olsen et al. 2003), eosinophil count among non-
asthmatic subjects (Dong et al. 2013; Emmett et al.
2006b), C-reactive protein (Costa et al. 2009; Lin
et al. 2011), wheezing (Granum et al. 2013; Humblet
et al. 2014; Okada et al. 2012, 2014; Smit et al. 2015),
eczema (Granum et al. 2013; Okada et al. 2012; Smit et al.
2015) (although a significant inverse association with
PFOA was found by Okada et al. (2014)), food allergy
(Granum et al. 2013; Okada et al. 2012), and otitis media
(Granum et al. 2013; Okada et al. 2012).
Specificity
No specific relationship was apparent between PFOA or
PFOS and any particular immune condition. However,
the overall lack of specificity does not provide evidence
for or against a causal conclusion (Hill, 1965). In the
study by Steenland et al. (2013), the specific relationship
of estimated PFOA exposure with prevalent ulcerative
colitis but not five other autoimmune disorders is
unlikely to be explained by bias particular only to
ulcerative colitis. However, the lack of a significant
association with prospectively ascertained incident
ulcerative colitis in that study may argue against a
causal interpretation of the association detected in the
retrospective analysis.
Temporality
The issue of temporality was discussed earlier in the
section on exposure assessment. Eleven of the reviewed
studies were cross-sectional or retrospective in design,
and were therefore unable to establish whether the
exposure preceded the outcome (Anderson-Mahoney
et al. 2008; Costa et al. 2009; Dong et al. 2013; Emmett
et al. 2006b; Humblet et al. 2014; Innes et al. 2011;
Kielsen et al. 2015; Lin et al. 2011; Looker et al. 2014;
Olsen et al. 2003; Uhl et al. 2013). The remaining studies
measured or estimated circulating PFOA and/or PFOS
levels before ascertaining immunological endpoints
(Ashley-Martin et al. 2015; Fei et al. 2010; Grandjean
et al. 2012; Granum et al. 2013; Okada et al. 2012, 2014;
Osuna et al. 2014; Pennings et al. 2015; Smit et al. 2015;
Steenland et al. 2015; Steenland et al. 2013; Wang et al.
2011) or, in the case of the retrospective cohort study,
evaluated occupational PFOA exposure prior to death
(Leonard et al. 2008). Thus, associations detected in the
second set of studies are temporally sequenced in a
manner consistent with a potential causal effect.
However, given the substantial uncertainty about the
magnitude of changes in circulating PFOA and PFOS
levels and some immune conditions over time, and
whether there exist certain time windows of exposure
susceptibility (and, if so, whether study exposures were
measured during those intervals), the prospective
measurement of PFOA or PFOS concentrations does
not substantially augment the quality of a study’s
evidence for or against a causal interpretation.
Biological gradient
Regression models in which circulating PFOA and PFOS
concentrations are analyzed on a continuous scale are
based on the assumption of a linear or log-linear
exposure-response gradient. Similarly, Pearson’s correla-
tion coefficients measure the strength of the assumed
linear relationship between continuous variables.
Studies that used these approaches generally did not
explicitly test the shape of the exposure-response curve.
Only Ashley-Martin et al. (2015) reported that they
explicitly tested the linearity of associations using
restricted cubic spline models, and they found no
significant non-linear associations between PFOA or
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PFOS and immune biomarkers. In addition, several other
studies classified PFOA or PFOS levels into ordinal
categories and tested for the presence of a monotonic
exposure-response trend across those categories. These
studies are described below.
Okada et al. (2012) found a curvilinear, overall inverse
relationship between maternal prenatal serum PFOA and
total IgE in cord serum among girls, but not boys. By
contrast, Dong et al. (2013) reported significant positive
trends between serum PFOA and PFOS quartiles and
serum total IgE, absolute eosinophil count, and eosino-
phil cationic protein among children with asthma, but
not those without asthma. In addition, the same authors
observed significant positive exposure-response trends
between serum PFOA and PFOS quartiles and risk of
asthma and, for PFOS, asthma severity. However, no
significant trend between tertiles of serum PFOA or
PFOS and ever or current asthma was reported by
Humblet et al. (2014). Okada et al. (2014) detected
significant inverse exposure-response trends between
maternal prenatal plasma PFOA (but not PFOS) quartiles
and risk of combined eczema, wheezing, and allergic
rhinoconjunctivitis symptoms (especially among girls)
and eczema alone in early childhood.
Fei et al. (2010) reported significant positive trends
between maternal prenatal plasma PFOA and PFOS
quartiles and hospitalization for infectious diseases in
early childhood among girls, but the opposite trends
were found among boys, resulting in a canceling out of
trends when both sexes were combined. Looker et al.
(2014) detected inverse trends between quartiles of
serum PFOA and post-vaccination titer increase and the
odds of seroconversion for anti-influenza type B anti-
body, but not other classifications of this outcome.
However, an opposite trend in the positive direction was
seen for serum PFOA quartiles and the odds of
seroconversion and seroprotection for anti-influenza
type A/H1N1 antibody, and no apparent monotonic
trends were seen between serum PFOA quartiles and
various classifications of the antibody response to
influenza type A/H3N2 vaccination. Serum PFOS quar-
tiles did not appear to exhibit any exposure-response
gradients with respect to the antibody response to these
three vaccine types.
Innes et al. (2011) observed a significant positive trend
between quartiles of serum PFOA and the prevalence of
osteoarthritis, especially among adults who were
younger than 55 years and not obese, countered by a
significant inverse trend with serum PFOS that was not
modified by age or obesity status. By contrast, increasing
quartiles of serum PFOA and PFOS were not associated
with monotonic change in the prevalence of osteoar-
thritis in the study by Uhl et al. (2013). Steenland et al.
(2013) found that the risk of ever having been diagnosed
with ulcerative colitis rose significantly in parallel with
increasing quartiles of estimated cumulative PFOA
exposure, but the risk of newly diagnosed ulcerative
colitis did not, nor did lifetime history of Crohn’s disease,
rheumatoid arthritis, insulin-dependent or type I dia-
betes, lupus, or multiple sclerosis, or incident rheuma-
toid arthritis. Positive exposure-response trends between
10-year lagged cumulative PFOA exposure and ulcera-
tive colitis, as well as positive trends with rheumatoid
arthritis, were also reported by Steenland et al. (2015) in
a subset of workers also included in the 2013 study.
Other outcomes, including C-reactive protein (Lin et al.
2011), atopic dermatitis (Wang et al. 2011), wheezing
(Humblet et al. 2014; Okada et al. 2014), and flu
infections and colds (Looker et al. 2014) were found
not to increase or decrease significantly in association
with rising categories PFOA or PFOS exposure.
Thus, although some significant increasing and
decreasing exposure-response gradients were found
for PFOA and PFOS with respect to various immune
conditions, thereby offering evidence consistent with a
causal mechanism, none were replicated across studies
or within studies that evaluated multiple comparable
outcomes. If sufficient data were available, it might also
be informative to compare results from occupationally
exposed workers, who have the highest PFOA and PFOS
exposure levels, with results from the Mid-Ohio Valley,
where PFOA exposure levels are comparable to back-
ground levels in PFOA plants, and results from general
populations, in which PFOA exposure levels are another
order of magnitude lower (Chang et al. 2014). However,
the lack of comparability in outcomes evaluated across
studies, as well as the small number of studies of any
given outcome, precludes such an analysis.
Plausibility and coherence
Experimental evidence of immunotoxic effects of PFOA
and PFOS in laboratory animals was briefly summarized
earlier in this review. In the absence of an established
mode of action/adverse outcome pathway, it is unclear
whether any of these findings can be translated to
humans and especially whether they are relevant to
clinically measurable human immunological disorders.
Synthesis of IgM, the main immunologic outcome
suppressed by PFOA in experimental animals (Corsini
et al. 2014; DeWitt et al. 2012), does not play a major role
in vaccine-related immunity, which is mediated mainly
by IgG. Thus, although animal evidence suggests that it
is biologically plausible that PFOA and PFOS could
adversely affect some aspects of immune function in
humans, it is also plausible that effects observed in
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animals are not directly applicable to humans. Given the
substantial differences in the types of immunological
outcomes measured in animal and human studies,
especially human studies of clinical immune conditions,
the coherence of epidemiologic and toxicological
evidence cannot be evaluated rigorously.
Experiment
The 3M Company, a major international producer of
PFOA and PFOS, phased out the manufacture and use of
PFOS by 2002 and PFOA by 2008 (U.S. EPA 2014), and
the world’s eight major fluoropolymer and telomere
manufacturers agreed to reduce PFOA emissions and
product content by 95% no later than 2010 and
completely by 2015 (U.S. EPA 2006). Consequently,
PFOS serum levels in the U.S. population have declined
steadily since 1999–2000, around the time that the 3M
phase-out began, and PFOA serum levels have also
declined since that time (except in 2007–2008) (CDC
2015). These circumstances create a natural experiment
by which one might examine whether the incidence of
certain immune conditions decreased in parallel with
documented declines in serum PFOS levels in the U.S.
population (Kato et al. 2011; Olsen et al. 2012), and
whether future anticipated declines in serum PFOA
levels might also be reflected in lower rates of immune
disorders. However, due to the lack of population-based
surveillance for the immune conditions of interest in this
review, as well as the high potential for confounding by
other time-dependent risk factors that may have
changed since the early twentieth century, such ecologic
data are unavailable to offer any evidence concerning a
causal hypothesis.
Analogy
Numerous analogies can be drawn to other chemicals
that cause immune disorders in humans, but just as
many can be drawn to other chemicals that do not. Such
analogies are tenuous and are not helpful for clarifying
the relationship of PFOA and PFOS to these conditions.
Conclusions
Based on a maximum of only seven epidemiologic
studies of any particular condition (asthma) and a body
of literature with major methodological limitations, an
evaluation of the weight of epidemiologic evidence
according to the Bradford Hill viewpoints reveals
generally weak associations, no specific endpoints with
consistent findings across all relevant studies, uncer-
tainty about any critical duration of exposure and
window(s) of susceptibility, mixed exposure-response
trends, and a dearth of supportive animal and mechan-
istic data. Thus, the available evidence is insufficient to
conclude that a causal relationship has been established
between PFOA or PFOS exposure and any immune
condition in humans. Most existing studies were cross-
sectional or retrospective in design, evaluated PFOA
and/or PFOS exposure at a single point in time, and
relied upon self-reported health outcomes. Going
forward, rigorously designed epidemiologic studies are
needed to shed new light on whether or not PFOA and
PFOS cause human immune disorders, and priority
should be given to conditions with suggestive positive
results in the available studies (e.g. ulcerative colitis).
When a clear link with clinical disease is lacking, as in the
case of subtle changes in immune biomarkers, immune
system impairment cannot be presumed. However, such
evidence might inform areas for additional research on
whether a mechanistic tie exists with clinically recogniz-
able health effects. In some study settings, linkages to
high-quality disease registries or administrative health
databases may enable connections to be drawn with
clinical outcomes.
As indicated throughout this review, greater knowl-
edge is needed on the magnitude and timing of intra-
individual variation in circulating PFOA and PFOS levels.
If serum or plasma levels of these chemicals are shown
to fluctuate over time, then studies should incorporate
repeated sampling to accurately capture variation in the
intensity, duration, timing, and trajectory of individual-
level exposure. For example, in prospective birth cohort
studies, multiple samples could be drawn during
gestation and, if immune conditions are assessed in
children rather than infants, during childhood.
In addition, to enable adequate control of confoun-
ders, more research is needed to identify the determi-
nants of personal PFOA and PFOS exposure, and studies
should collect sufficiently detailed data on these
determinants to permit statistical adjustment. For
example, factors that have been shown to affect serum
PFAS concentrations in the general population, and that
could confound associations with certain health out-
comes, include age, sex, race/ethnicity, education,
income, body size, tap water consumption and filtering,
diet and total energy intake, cooking methods, smoking
status, alcohol intake, caffeine consumption, and preg-
nancy and breastfeeding status (Calafat et al. 2007b;
Emmett et al. 2006a; Eriksen et al. 2011; Jain 2013, 2014;
Nelson et al. 2012; Tyrrell et al. 2013).
Other design features that will help to produce more
informative data include prospective follow-up to clarify
the temporal relationship between exposure and out-
come and reduce information bias; collection of
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complete, accurate, reliable, and clinically relevant
health outcome data using medical records or direct
assessment with validated and standardized tools; and
enrollment of large numbers of subjects with sufficient
variation in exposure levels to enable detection of any
corresponding health differences. In addition, a priori
hypotheses and post hoc exploratory analyses should be
explicitly described, null results should be fully reported,
and the potential influence of bias and chance should be
thoughtfully considered, along with quantitative sensi-
tivity analyses to the extent possible. These improve-
ments will help to clarify whether the lack of persuasive
evidence is due to a shortage of well-designed
epidemiologic studies or the absence of a true demon-
strable immunotoxic effect of these chemicals. At
present, however, the epidemiologic evidence does
not establish a causal effect of PFOA or PFOS on
immune conditions in humans.
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